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ABSTRACT 
 
 
The signal transduction network controlling protein degradation in the striated body-wall muscle 
of C. elegans has been shown to be composed of stimulatory signaling from the FGF receptor and 
inhibitory signaling from the IGF receptor engaged in cross talk at the level of the Raf-MEK-
MAPK cascade.  Calcium/calmodulin-dependent protein kinase II (CaMKII) is an additional, pro-
degradation input into the network at the level of Raf.  Splice forms of CaMKII may play a role in 
effective CaMKII signaling.  The IGFR/FGFR/CaMKII network regulates protein degradation via 
autophagy.  Degradation caused by increase of the pro-degradation signal from CaMKII can be 
suppressed by increase of opposing IGFR signaling, and degradation caused by decrease in the 
IGFR signal can be suppressed by decreased CaMKII signaling.  This implies that regulation of 
protein degradation is based on integration of multiple signals by Raf and not on absolute amounts 
of individual signals.  
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1.0  INTRODUCTION 
Muscle is a tissue of interest for many groups of people, including athletes, astronauts, the 
injured, and the elderly, just to name a few.  Athletes seek to maximize muscle performance and 
avoid injury, while astronauts, the injured, and the elderly seek to avoid or reverse loss of muscle 
mass.  While these groups may have an increased awareness of the importance of muscle, all 
people require muscle for movement (skeletal muscle), breathing (smooth muscle), and beating of 
the heart (cardiac muscle).  Although dysfunction of muscle, particularly skeletal muscle, caused 
by aging or medical problems is not always a direct cause of death, function of muscle contributes 
to quality of life.  As we come to focus more on “health span”, we are likely to also focus more on 
our muscle and its role in our lives [7]. 
Skeletal muscle is the type of muscle we use for locomotion, and perhaps less obviously, 
as a metabolic reserve of protein.  When one compares the muscle of, for example, a young athlete 
and an elderly person, one notices differences in both strength and mass.  While the structural 
differences between the muscles in these individuals are well-catalogued [8-13], the molecular 
biology and biochemistry of each state are more complicated.  This study attempts to broaden our 
understanding of how muscle responds to the signaling environment to determine the appropriate 
extent of protein catabolism.  We do this using C. elegans body-wall muscle as a model, since it 
is related to human skeletal muscle and C. elegans offers many benefits as a model system.  
Perhaps the most important advantage is that by using C. elegans we can look at muscle in situ, an 
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important benefit when one considers the various paracrine and endocrine signals a tissue is 
exposed to in a whole, living animal.  Using this system, I will show calcium/calmodulin-
dependent protein kinase (CaMKII) promotes degradation through interaction with other known 
signaling pathways and that these pathways regulate protein degradation via autophagy.  I will 
start to define the rules by which signaling through these multiple pathways is integrated and offer 
some data on the role that a specific isoform of CaMKII may be playing in promoting CaMKII 
activation and degradation. 
In the following introduction to this work, I will first discuss the different types of muscle, 
focusing on skeletal muscle and its contractile and metabolic roles.  I will then describe the effects 
of skeletal muscle hypotrophy and the degradative mechanisms by which it occurs.  Having 
described relevant muscle types and processes in vertebrates, I will describe the parallel structures 
and processes in C. elegans, as well as the signaling pathways regulating muscle protein 
degradation that we have thus far identified using this system.  Lastly, I will turn to calcium 
signaling and the role it is known to play in muscle protein homeostasis, preparing the reader for 
my studies of CaMKII, a protein most succinctly described as a calcium sensor, and its role in 
muscle protein degradation. 
1.1 ROLE OF MUSCLE IN HEALTHY ANIMALS 
1.1.1 Types of muscle 
In vertebrates, there are three different types of muscle: smooth, cardiac, and skeletal.  
Smooth muscle is non-striated, while cardiac and skeletal muscle are striated [14].  
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Developmentally, skeletal muscle originates from somites, which are segments of the paraxial 
mesoderm that lie in pairs along the neural tube.  Each somite differentiates to produce 
dermomyotome, which goes on to produce muscle precursors that migrate to the limbs and body 
wall and become the muscles of the back [15].  Cardiac muscle is derived from two populations 
of cells in the anterolateral plate mesoderm called the right and left heart fields.  The two fields 
merge anteriorly and then form a tubular heart, which is specified along its anteroposterior axis to 
form what will become the compartments of the mature heart.  The tube undergoes looping and 
acquires contractile activity [16].  Smooth muscle cells have diverse origins, both from the 
ectoderm and mesoderm.  Some smooth muscle cells arise from the cardiac neural crest, while 
others arise from the local mesenchyme [17]. 
All three types of muscle express some of the same muscle-specific genes from 
embryogenesis, while they also each express genes unique to their particular muscle type.  This 
allows all three tissues to be defined as “muscle”, but gives them unique contractile, metabolic, 
and electrophysiological properties [15, 18].  These muscle-specific genes that are differentially 
expressed in the various muscle types are regulated by the binding of transcription factors.  With 
each gene able to bind multiple transcription factors, it is the combination of factors bound to 
regulatory regions of the gene that confers level of expression [15].  The combinations of genes 
that are expressed then define a muscle type and gives rise to its particular muscle structure and 
function.   
 As stated above, smooth muscle is a non-striated form of muscle.  Layers of smooth muscle 
are contained in the walls of various organs and blood vessels.  Their contraction serves to move 
the luminal contents of the organ or vessel in which they reside [19].  Although they are not 
striated, contraction still occurs through interaction of myosin with actin stimulated by a change 
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in electrical potential of the cell membrane.  Upon stimulation, calcium is released from the 
internal sarcoplasmic reticulum (SR) stores and enters from the extracellular space.  Calcium then 
binds to calmodulin, which binds myosin light chain kinase (MLCK).  Binding of 
calcium/calmodulin to MLCK results in removal of the autoinhibitory domain from the active site 
and activation of the kinase [20].  MLCK then goes on to phosphorylate myosin light chain, 
promoting myosin’s ATPase activity and causing cross-bridge cycling and contraction.  Relaxation 
is promoted by decreased activity of MLCK and increased activity of myosin light chain 
phosphatase.  Interestingly, activity of autophosphorylated CaMKII (see section 1.4.3) promotes 
relaxation of smooth muscle by phosphorylating MLCK on a site that prevents binding of 
calcium/calmodulin [21]. 
 Cardiac muscle is a type of striated muscle more closely related to skeletal muscle.  In the 
heart, myocytes are arranged in muscle fibers, which are organized to form the myocardium and 
the ventricles of the heart [22].  Electrical stimulation of the myocytes causes them to contract and 
increase the pressure inside the ventricle to the point where the valve opens.  When the valve 
opens, the tissue is deformed and blood is ejected [22].  There are two different types of myocytes, 
work cells and pacemaker cells.  Work cells have a more stable resting potential, while pacemaker 
cells have unstable resting potentials and spontaneously depolarize to generate the auto-
rhythmicity of the heart [23].  Influx of calcium into the myocyte from the extracellular space 
stimulates further release of calcium from the SR.  Unlike smooth muscle, cardiac muscle contains 
troponin, which is associated with the actin filament and prevents interaction of myosin with actin.  
Binding of calcium to troponin causes a conformational shift that permits the interaction of actin 
and myosin.  The activity of myosin in cardiac muscle does not require MLCK, but its activity can 
be modulated by it.  Additionally, MLCK in cardiac muscle has roles in maintaining sarcomere 
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structure [24].  In cardiomyocytes, activated CaMKII is linked to heart failures and arrhythmias 
through phosphorylation of diverse downstream substrates [25].   
 Skeletal muscle is multinucleate and striated.  Bundles of multinucleate fibers are bound 
to form the whole muscle, which is sheathed in connective tissue continuous with the tendons at 
the end of the muscles [2].  Contraction of skeletal muscle allows for movement.  In skeletal 
muscle, depolarization activates a calcium channel in the plasma membrane (the L-type channel) 
that physically interacts with the calcium channel in the SR (the ryanodine receptor, RyR).  This 
activation results in a small influx of calcium and activation of the opposing channel on the SR, 
which releases a large amount of calcium into the muscle cytoplasm.  Excitation-contraction 
coupling is similar to that in cardiac muscle and MLCK plays a negligible role [24].  The structural 
features of skeletal muscle will be further discussed in the following section.  
1.1.2 Structure of skeletal muscle  
Developmentally, skeletal muscle arises from structures of the paraxial mesoderm, called 
somites.  Dorsally, each somite contains dermomyotome, which differentiates to produce 
dermatome and myotome [26].  The dorso-medial dermatome and myotome produces the back 
muscles, while the ventro-lateral dermatome produces the trunk and limb muscles [27].  These 
populations give rise to the direct precursors of muscle cells, myoblasts.  Myoblasts are 
mononucleate cells that are defined by their expression of myogenic regulatory factors [27].  
Myoblasts fuse and migrate to their future location, where they attach to the appropriate tendon 
[28].   
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The same embryonic myogenic precursor cells that give rise to muscle also give rise to 
satellite cells [26], which are non-differentiated, muscle-precursor cells that are external to, but 
associated with muscle fibers [2].  Upon stimulation, satellite cells differentiate into myoblasts that 
are capable of differentiating into adult muscle fibers [5].  These cells are essential for muscle 
growth, repair, and adaptation [2].     
The basic structural unit of a skeletal muscle is a muscle fiber (Figure 1).   A muscle fiber 
is a multinucleated cell containing many parallel myofibrils, the contractile apparatus of the muscle 
cell.  Each muscle fiber is innervated by a single branch of a motor neuron [5] and is surrounded 
by connective tissues called endomysium [2]  One muscle fiber combined with other muscle fibers 
and innervated by the same neuron compose a motor unit.  In contrast to smooth muscle and cardiac 
muscle, skeletal muscle activation is voluntary, with a motor unit being the smallest group of 
muscle fibers that can be voluntarily activated, as all fibers in a motor unit will contract 
simultaneously as they are depolarized by a nerve impulse.  Motor units range in size from several 
dozen to thousands of fibers [5].  Muscle fibers are bundled in fasciculi, which are surrounded by 
perimysium [2].  Fibers in different motor units can be in the same fasciculus, and vice versa, 
although all fibers in the same motor unit are of the same type, as will be discussed below.  
Fasciculi are bundled to form the complete muscle, which is sheathed in epimysium [2].  (Figure 
1) 
The basic contractile unit of a muscle fiber is the sarcomere, with an array of parallel, 
longitudinally repeating sarcomeres forming a myofibril [2].  As muscle develops post-natally and 
through adulthood, muscle fiber increases in length by adding sarcomeres longitudinally [29].  A 
sarcomere is composed of overlapping thin (actin) and thick (myosin) filaments that slide across 
each other during muscle contraction [5].  Thin filaments are composed of actin, tropomyosin, and 
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Structure of a mammalian muscle.  Longitudinally repeating sarcomeres are arranged in parallel 
to form a myofibril.  Several myofibrils are bundled to form a muscle fiber.  Bundled muscle 
fibers form a fasiculus.  Many fasciculi form the complete muscle. Adapted from Exeter, 2010 
[2] and Brooks, 2003 [5] 
Figure 1  
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troponin.  Two chains of actin and a chain of tropomyosin are twisted together  
in a helix.  Troponin is a globular protein consisting of three subunits and is bound to tropomyosin 
[2].  Thick filaments are composed of myosin heavy chain (MHC) proteins arranged in bundles of 
two, with each bundle having a rod-like portion and two globular heads [2].  At the neck of the 
head, myosin light chain is associated.  It is the head of the MHC that binds actin and ATP [2]. 
Contraction of the muscle cell depends on calcium binding to troponin, leading to an 
alteration in the conformation of the thin filament such that the myosin head can bind it.   Calcium 
enters the sarcoplasm of the muscle cell from both the external environment and the internal stores 
of the SR.  The SR is closely associated with the myofibrils, such that the calcium that is released 
from the SR upon stimulation of the muscle cell will be at its site of action.  To avoid the classic 
surface/volume ratio problem in communicating a nerve impulse to all the myofibrils in a muscle 
fiber, the plasma membrane has a system of deep invaginations that form tubules.  These are called 
transverse (T) tubules.  Each T tubule is abutted on either side by dilations of the sarcoplasmic 
reticulum, in an arrangement called a triad [2].  The role of these structures in contraction will be 
discussed in the following section, as will the implications of modulation of these structures on 
muscle strength. 
1.1.3  Muscle as a means for doing mechanical work  
In order to contract, the muscle must be stimulated by a nerve impulse.  A nerve impulse 
results in release of acetylcholine (ACh) into the neuromuscular junction (NMJ).  Binding of 
acetylcholine to ligand-gated sodium channels (acetylcholine receptor, AChR) results in flux of 
sodium into the muscle cell, leading to depolarization of the muscle membrane [2].  This 
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depolarization enters the T-tubule and causes a change of conformation of the dihydropyridine 
receptor (DHPR), an L-type calcium channel.  Some calcium can enter the cell through the DHPR, 
but this is not required for muscle contraction [30].  Instead, physical interactions between the 
DHPR and the RyR during depolarization stimulate release of SR stores of calcium through the 
RyR into the muscle cytoplasm [30]. 
In order for contraction to occur, the globular head of MHC must ratchet along the actin 
filament in a series of events known as cross-bridge cycling, with a “cross-bridge” being the 
interaction between the myosin head and actin, and “cycling” referring to the fact that contraction 
occurs by a cycle of binding and release of the actin filament by myosin.  Upon stimulation of the 
muscle cell, the calcium released from the sarcoplasmic reticulum binds troponin.  This initiates a 
conformation shift in the actin filament, exposing the myosin binding sites.  Myosin-bound to ATP 
is then able to bind actin, marking the start of the cross-bridge cycle.  Next, myosin hydrolyzes the 
ATP, releasing ADP and inorganic phosphate and causing distortion of the myosin head, to pull 
on the actin filament.  Rebinding of ATP to myosin causes release of the actin filament and return 
of the myosin head to its original conformation.  Repetition of this cycle causes the actin and 
myosin filaments to slide along each other and the sarcomere to shorten. [31] 
When stimulation of the muscle cell ceases, calcium is returned to the SR via the 
Sarco/Endoplasmic Reticulum ATPase pump (SERCA).  SERCA pumps two calcium ions into 
the SR for every mole of ATP converted to ADP, Pi, and heat, creating a 10,000-fold concentration 
gradient [32].  Return of calcium to the SR results in loss of cross-bridging. 
It is the rate of the cross-bridge cycle that determines the velocity with which a muscle 
fiber can shorten.  The rate of cycling is determined by the ATPase activity of the MHC [5], of 
which there are many isoforms, each with characteristic ATPase activity.  The types of MHC 
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expressed in a muscle will determine the shortening velocity of that muscle.  The power of a 
contraction [33] is equal to force times velocity, with force being determined by the cross-sectional 
area of the fiber, or the number of myofibrils in parallel [29].  The various MHC isoforms do not 
have different abilities to generate force, so variations in power output by muscle expressing 
different MHC isoforms is based on differences in shortening velocity [5].  It is muscle power that 
is needed for athletic movements.  During growth and adaptation, the isoforms of MHC expressed 
in a muscle changes [29].   
Another important component of muscle performance is resistance to fatigue.  This 
depends on continuation of the cross-bridge cycle.  ATP is required for the cross-bridge cycle to 
turn, therefore it is the availability of ATP that determines fatigue resistance.  ATP is generated by 
oxidative metabolism, requiring mitochondria.  To increase fatigue resistance, muscle increases 
the number of mitochondria.  However, due to space considerations, an increase in mitochondria 
reduces the packing density of the myofibrils, which reduces the amount of force that can be 
generated.  Therefore, there is trade-off between power and endurance.  Based on the demands 
placed on a motor unit, its component fibers will be fast-twitch and favor the fast type of MHC 
with fewer mitochondria, or slow-twitch and favor the slow type of MHC with more mitochondria.  
It is not entirely understood how these changes in gene expression occur.  [29] 
Another way a muscle can increase power output is by adding sarcomeres longitudinally 
to the muscle fiber in order to produce sarcomeres of optimum length for power output [29].  
Stretching and stimulation induces lengthening of the muscle fiber and is associated with increased 
protein synthesis [29].  This change is thought to require not so much a change in what genes are 
expressed by the muscle, but by the amount of translation of expressed genes [29]. 
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With age, muscle mass and maximal power output decrease (sarcopenia).  This is largely 
due to loss of muscle fibers, with fast fibers more prone to loss than slow fibers [34].  This loss is 
caused by denervation of the fast muscle fibers, which may or may not be re-innervated by sprouts 
from the nerves that innervate slow muscle fibers.  Those that are not re-innervated are lost [34].  
Aging muscle is also less able to generate force per muscle fiber cross-sectional area than younger 
muscle.  This deficit is thought to be the result of accumulation of insufficiently repaired 
contraction-induced damage [5], the repair of which is thought to be the primary mechanism by 
which muscle adaptation occurs [2].   
1.1.4 Muscle in metabolism  
Muscle is classically regarded as a tissue whose primary role is to produce movement.  
While its role in locomotion is important, it has an equally important metabolic role.  In this 
metabolic role, it serves both as the body’s “furnace” through thermogenesis [35] and as the body’s 
primary location of stored protein [36].   All heat production in muscle is ultimately tied to 
hydrolysis of ATP [32]. Hydrolysis of ATP during muscle contraction produces heat, but skeletal 
muscle is likely also responsible for a significant amount of resting, basal heat production [32].  
This heat may be produced by maintenance of muscle tone [32], as a byproduct of absorption and 
storage of nutrients [37], or, majorly, by calcium ion recycling [32].  It is thought [32] that the 
steep calcium gradient between the SR and the cytoplasm causes leakage of calcium from the RyR.  
This “leaked” calcium is pumped back into the SR by SERCA, generating heat through hydrolysis 
of ATP [32].  Production of heat is balanced by heat dissipation, resulting in maintenance of basal 
body temperature, 37C for humans [38].  Mutation of proteins involved in calcium recycling (often 
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the RyR) can cause malignant hyperthermia with use of anesthetics [32].  Anesthetics cause 
increased calcium leakage through mutant RyR, leading to an increase in intracellular calcium.  
This increased intracellular calcium causes a decrease in cytoplasmic ATP and an increase in 
glycolysis, generating heat [32].  Excess calcium is taken up by the mitochondria, increasing 
oxidative metabolism and heat production [32].  Untreated, malignant hyperthermia results in 
death. 
Muscle’s role as a protein-storage organ in likewise important.  Muscle contains half of all 
protein in a healthy human and acts as a protein reservoir [36]. This protein reservoir is maintained 
so that in times of need, such as starvation or disease, it can be readily tapped as a source of amino 
acids for energy metabolism or biosynthesis by organs which require a steady source of amino 
acids [39].    During fasting, muscle releases amino acids into the circulation, as well as 
gluconeogenic precursors.  The amino acids are used by other tissues for essential protein synthesis 
[40], while the gluconeogenic precursors are used by the liver for production of the glucose needed 
to keep the body alive and feed the brain [41].  In fasting and non-fasting states, muscle also 
provides the amino acids required for neurotransmitter synthesis and acid/base balance [29].   
During catabolic conditions, such as cancer, diabetes, burn injury, or sepsis, the muscle 
releases amino acids that are used not only as described above, but also for wound healing and the 
synthesis of antibodies and acute-phase proteins [42], [36].  Therefore, these conditions require 
protein breakdown in excess of what occurs during fasting, and in some cases, such as extensive 
burn injury, can require amounts of proteins 4 times in excess of the normal daily intake [40].  This 
need for excess protein can trigger net breakdown of muscle protein that is difficult to reverse by 
nutritional support [40].    In fact, patients suffering from trauma or critical illness are less likely 
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to survive or fully recover if they had lower levels of lean body mass [40].  In the following section 
I will discuss in more detail the effects and mechanisms of skeletal muscle wasting.   
1.2 SKELETAL MUSCLE WASTING 
1.2.1 Role of muscle wasting in disease 
While muscle protein catabolism can provide tissues with needed amino acids, excessive 
catabolism of muscle protein can lead to muscle wasting [43], which is characterized by loss of 
muscle mass and function.  Muscle wasting, as seen in patients with catabolic diseases, is caused 
primarily by increased muscle protein degradation [44], and can lead to death through failure of 
the diaphragm muscle [45] or the inability to produce the glutamate required to survive a traumatic 
experience [29].  In contrast to loss of skeletal muscle caused by starvation, the loss of skeletal 
muscle observed in patients with aging, chronic diseases, or injury cannot be easily reversed [46]. 
After feeding, protein synthesis in skeletal muscle doubles and accounts for more than half 
of all the protein synthesis occurring in the body [47].  Protein anabolism by muscle is regulated 
by the plasma concentrations of amino acids and insulin [48].  Muscle wasting is caused by an 
imbalance in the amount of muscle protein synthesis and protein degradation.  Strategies for 
treating muscle wasting can then focus either on increasing protein synthesis or decreasing protein 
degradation.  Unfortunately, increased nutrient intake does not increase protein anabolism in many 
disease states, suggesting that signaling mechanisms of the disease state are not only enhancing 
degradation, but also inhibiting synthesis.  Signaling mechanisms of catabolic diseases include 
glucocorticoids, cytokines, and oxidative stress, which have all been shown to have negative 
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impact on the pathways that normally promote anabolism [48].  This effect, as seen in catabolic 
diseases, has been described as a raise in the “anabolic threshold” [48].   
Instead of trying to reset the anabolic threshold, treatments for muscle wasting often focus 
on increasing amino acid intake to reach the new anabolic threshold.  Particularly, supplementing 
with leucine stimulates protein synthesis, even in the absence of insulin and other amino acids 
[49].  Still, leucine consumption has been shown to have the most marked effect when taken as 
part of a whole protein (such as whey protein) and taken all at one meal [48]. 
An alternative treatment for muscle wasting is to lower the anabolic threshold by modifying 
the signaling pathways that have led to its rise.  A benefit of this strategy is that it would not require 
complicated feeding schedules and would eliminate the burden placed on nitrogen waste removal 
mechanisms caused by high protein intake, a matter of important consideration in patients who are 
frail or have impaired renal function [48].  Despite the fact that many of the signaling pathways 
causing this rise in the anabolic threshold have been identified, treatments based on this strategy 
have been largely unexplored [48], mostly due to the complicated nature of trying to re-balance 
multiple signaling pathways to re-establish a healthy anabolic threshold. 
1.2.2 Mechanisms of protein degradation  
Degradation can be carried out by lysosomal and non-lysosomal mechanisms.  Non-
lysosomal mechanisms include the ubiquitin-proteasome system, calpains, and caspases, while 
lysosomal mechanisms include autophagy [50].  I will briefly discuss the ubiquitin-proteasome 
system, calpains, and caspases here, although the focus of this work will mostly be on autophagy 
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and its regulation.  This review of non-lysosomal degradative systems will provide a contrast to 
the mechanisms of autophagy. 
The ubiquitin-proteasome system primarily degrades proteins that have been tagged with 
ubiquitin for degradation.  Ubiquitin is a small, 76 amino acid protein.  It has a carboxy-terminal 
glycine residue that is essential for conjugation to other proteins and several lysine residues that 
are used in making polyubiquitin chains [51].   
Tagging of a protein by ubiquitin is a highly regulated process, involving the action of three 
ubiquitin ligases (E1-E3).  The E1 is the ubiquitin-activating enzyme.  In mammals, there is only 
one E1.  Once activated, a ubiquitin can be transferred to an E2, a carrier protein.  Finally, an E3 
transfers the ubiquitin to the target protein.  The target can either become mono-, multi-mono-, or 
polyubiquitylated.  Polyubiquitylation occurs when several ubiquitins are attached in a single chain 
to the substrate.  Polyubiquitin chains that are greater than five in length signal for protein 
degradation [44].  These chains are usually Lys48- and Lys11-linked chains [52].  The type and 
length of chain is regulated by the E2 [52], of which there are about a dozen in mammals [53], 
providing a level of specificity and discrimination [51].  
The action of the E3 provides even greater specificity to the proteasomal process.  Different 
tissues express different sets of E3s, resulting in tissue-specificity in the proteins degraded by the 
proteasome.  In muscle, the E3 ligases antrogin-1 and MuRF-1 are more highly expressed during 
atrophy, and mouse models of starvation and denervation show reduced atrophy when these genes 
are knocked out [51].  These E3s have come to be used as biomarkers for atrophy.  
Ubiquitinated proteins are recognized by the proteasome.  The proteasome is a large, 60-
subunit, protein-degrading machine.  The 19S regulatory particles on the ends of the 20S barrel 
are responsible for recognizing and removing the ubiquitin chains prior to degradation [51].  The 
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de-ubiquitinated protein is unfolded and translocated into the 20S barrel through an ATP-
dependent process.  Inside the barrel, the protein is cleaved into peptide fragments.  When these 
fragments exit the proteasome, they are degraded into their constituent amino acids by endo- and 
aminopeptidases.  [51] 
Fasting and denervation stimulate ATP-dependent protein degradation 2- to 3-fold in rat 
leg muscles ([44], [54]) and rat skeletal muscle shows an increase in ubiquitin- conjugated proteins 
during fasting and denervation.  This is accompanied by increases in ubiquitin and proteasome 
mRNA, despite decreases in total mRNA [55].  These increases suggest that there may be a change 
in the “transcriptional program” during altered states that lead to atrophy [53]. 
Two transcription factors implicated in proteasomal protein degradation in muscle are 
FoxO and NF-kB.  FoxO and NF-kB bind the promoters of antrogin-1 and MuRF-1, respectively.  
In both the case of FoxO and NK-kB, inhibition prevents atrophy and activation causes it [56, 57].   
The ubiquitin-proteasome system can only very slowly degrade myofibrils, so they must 
initially be cleaved by other cytosolic proteases [51].  Evidence suggests that calpains and caspases 
play this role [51].  The role of calpains and caspases will be discussed in section 1.4.3. 
Macroautophagy is responsible for the degradation of long-lived proteins and organelles 
[3].  It occurs at a basal level in healthy tissue and in muscle is required to maintain mass [50] and 
prevent myopathy [58].  Up-regulation of autophagy under conditions such as growth factor 
withdrawal, structural remodeling, protein aggregate accumulation, etc., can be adaptive, but 
excessive autophagy contributes to muscle loss [59].   
Autophagy is negatively regulated by TOR kinase.  In response to growth factors and 
nutrients, TOR turns off autophagy [3] by phosphorylating ATG13 and preventing its interaction 
with ATG1 [60] (yeast gene names used throughout).  Inactivation of TOR leads to 
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dephosphorylation of ATG13 and its subsequent association with ATG1.  This interaction is 
stabilized by ATG17 [60] and activates the kinase activity of ATG1 [61].  The formation of this 
complex is required for autophagy, however it is not understood how this complex promotes 
autophagy [62].  One study [63] suggests that ATG17 is a scaffold required for recruitment of 
other Atg proteins to the pre-autophagosomal membrane.  (Figure 2) 
The autophagosomal membrane is a double membrane, whose origin is not entirely known.  
It begins to form at a punctate structure called the phagophore assembly site (PAS), the structure 
of which is unknown [63].  ATG proteins are recruited to the PAS, resulting in the nucleation or 
expansion of the phagophore [64].  The phagophore is a small membrane sac that will elongate 
and curve to eventually form the closed autophagosome and is also known as the “isolation 
membrane” [62].   
Phosphatidylinositol 3-phosphate (PI3P) is required for formation of the autophagosome, 
although it is not known why.  It may possibly be involved in changing the membrane dynamics 
of the phagophore origin membrane, or it may simply recruit binding partners required for 
phagophore formation [65].  PI3P is formed by a type III phosphatidylinositol 3-kinase (PI3K) 
called Vps34.  Vps34 is in a complex with ATG-14, ATG-6 (Beclin-1), and Vps15 [62] (Figure 
2).  ATG-14 (not shown) localizes the rest of the complex to the PAS though its interaction with 
ATG-6, which is a binding partner of Vps34 and promotes its association with Vps15 [62].  Vps15 
increases the kinase activity of Vps34 and is required for its responsiveness to autophagy induction 
[62]. 
The ER is one of the suspected origins of the membrane that makes up the phagophore.  
ATG14 localizes to the ER during starvation and the ER has increased PI3P content during 
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Figure 2 
Stages of autophagy.  Autophagy is induced upon relief of inhibition by TOR.  After 
induction, an isolation membrane forms and elongates until it forms a complete 
autophagosome.  The autophagosome fuses with the lysosome and its contents are degraded.  
From Levine, 2008 [3]. 
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starvation [65].  Upon starvation, structures called “omegasomes” are formed on the ER and are 
proposed as platforms for phagophore formation [65]. 
Expansion of the phagophore requires two conjugation systems, ATG8 (MAP-LC3) and 
ATG12 [65] (Figure 2).  Both ATG8 and ATG12 are ubiquitin-like proteins, which, although they 
have no sequence homology to ubiquitin, have similar folds and substrate attachment systems [65].  
ATG12 is activated by an E1-like enzyme, transferred to an E2-like enzyme, and finally covalently attached to ATG5.  ATG12-ATG5 then 
associates with ATG16L and oligomerizes to form a large complex [65].  In a similar series of 
steps, ATG8 becomes covalently attached to phosphatidylethanolamine (PE), with ATG12-ATG5 
bound to Atg16L acting as the E3 ligase [65].  ATG12-ATG5 bound to ATG16L seem to have the 
primary function of conjugating LC3 to PE.  Lipidated LC3 is associated with inner and outer 
autophagosomal membranes.  The outer LC3 is not destroyed by maturation of the autophagosome, 
and is later cleaved off and recycled, so LC3 is a marker of both developing and mature 
autophagosomes.  LC3 is thought to act as a scaffold to support expansion or deformation of the 
phagophore, as well as an adaptor-coat molecule aiding in cargo selection [65].     
Mature autophagosomes can fuse with each other, with endosomes, or with lysosomes [66].  
Fusion with the lysosome can either be complete, or can be of the “kiss-and-run” variety, where 
the autophagosome and the lysosome associate, exchange membrane and content, and disassociate 
[66].  It is unknown what effect these different types of association have on the degradation of 
autophagic contents [66].   
Degradation of muscle protein involves both the degradation of myofibrillar and non-
myofibrillar proteins, which are differentially regulated [67], [68].  Non-lysosomal mechanisms 
have been implicated in the degradation of myofibrillar proteins, while lysosomal degradation 
plays a role in the degradation of non-myofibrillar proteins [67], [69].  Although they are 
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differentially regulated, myofibrillar and non-myofibrillar degradation are often concomitant.  For 
example, in vitro studies of denervated rat soleus muscle show that myofibrillar protein is degraded 
by non-lysosomal mechanisms, but that total protein degradation can be enhanced by combining 
denervation and conditions that promote lysosomal proteolysis, such as low insulin, low amino 
acid, or high calcium [69].  In disease states, protein degradation is most likely a combination of 
myofibrillar and non-myofibrillar degradation, although, historically, myofibrillar degradation has 
been easier to study in vivo through measuring release by the muscle of 3-methyl-histidine (post-
translationally modified histidine found in contractile proteins). We have therefore developed C. 
elegans as a model with which to study the degradation of soluble muscle proteins.  
1.3 C. ELEGANS AS A MODEL TO STUDY MUSCLE PROTEIN DEGRADATION 
1.3.1 C. elegans muscle structure* 
In C. elegans, muscle is categorized based on whether it has multiple or single sarcomeres 
[70].  The muscle with multiple sarcomeres is obliquely striated, with sarcomeres attached to the 
hypodermis and the cuticle.  Body-wall muscle falls into this category.  C. elegans body-wall 
muscle is broadly similar in structure and function to human skeletal muscle [71].  There are four 
                                                 
* Information in this section was obtained from the Muscle System chapter of WormAtlas, available at 
http://www.wormatlas.org/hermaphrodite/muscleintro/MusIntroframeset.html.  I have included one citation for each 
sub-section of the chapter used, although all information in section 1.3.1 was obtained from this source, unless 
otherwise noted.  
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quadrants of body-wall muscle, composed of 95, mononucleate cells [72].  Two of the quadrants 
are dorsal and two are ventral.  Each is composed of a double row of muscle cells extending the 
length of the body and is ensheathed in the basal lamina.  Each cell is composed apically of the 
myofilament lattice and basally of the “muscle belly”, which contains the nucleus, cytoplasm, and 
mitochondria.  (Figure 3) 
Two myosin proteins are present in C. elegans skeletal muscle, MHC A and MHC B.  MHC 
A is encoded by myo-3 and MHC B is encoded by unc-54.  Additionally, two other muscle myosins 
encoded by myo-2 and myo-1 are expressed only in the pharyngeal muscle.  The myosins in body-
wall muscle form homodimers before assembling to form the thick filament.  When they assemble, 
MHC A forms the center of the filament, while MHC B assembles on either end.  MHC A is 
thought to have some role in nucleation of the filament.  As in many invertebrates, the thick 
filament of C. elegans also contains paramyosin at its core.  Paramyosin has a structure similar to 
the rod portion of MHC.  The actin filament in C. elegans is very similar to that of vertebrate 
skeletal muscle, in that it contains actin, tropomyosin, and troponin.  [73] 
As in vertebrates, the sarcomeres are composed of interdigitated thick and thin filaments.  
Thin filaments are anchored to the dense body, the analog of the vertebrate Z-disc, while thick 
filaments are anchored to an M-line analog.  The depth of the myofilament lattice is equal to the 
length of the dense bodies (approx. 1 µm), which anchor all filaments to the cell membrane, 
hypodermis, and cuticle.  The network of the sarcoplasmic reticulum (SR) surrounds the 
myofilament lattice, as well as the dense body and the apical plasma membrane.  The apical plasma 
membrane in contact with the SR contains voltage-gated calcium channels, while the SR 
membrane contains RyRs.  (Figure 3)  
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Figure 3 
C. elegans muscle structure.  The myofilament lattice is composed of sarcomeres and anchored 
to the cuticle.  The myofilament lattice extends into the muscle belly of the muscle cell, which 
contains the mitochondria and nucleus.  Muscle cells are arranged in longitudinal rows to form 
the four muscle quadrants.  Adapted from Hobert, 1999 [1]. 
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Since the SR directly apposes the plasma membrane with only a 12-14 nm gap, no T-tubule 
system for coupling of excitation and contraction is required, especially since calcium release from 
the SR through the RyR aids in motility, but is not required.  C. elegans muscle also does not 
contain voltage-activated sodium channels.  Action potentials are instead generated by influx of 
calcium through voltage-gated calcium channels (L-type).  It is the influx of calcium though these 
channels that triggers contraction. 
The body muscles are innervated by motor neurons arising from the dorsal or ventral nerve 
cord, which contain cholinergic, stimulatory motor neurons and GABAergic, inhibitory motor 
neurons.  The neck muscles are innervated by the ventral nerve cord and the nerve ring motor 
neurons.  Head muscles are innervated only by the nerve ring motor neurons.  Due to this pattern 
of innervation, the body muscles are only capable of making dorsoventral bends, whereas the head 
and neck muscles can also make lateral movements.  
The neuromuscular junction in C. elegans also has its differences from those of vertebrate 
muscle.  In C. elegans the muscle sends out arms to meet the motor neuron, housed in the nerve 
cord.  Even at the neuromuscular junction, the muscle cell remains separated from the nerve cord 
by the basal lamina.    Each muscle cell sends out multiple arms to the nerve cord, and each arm 
varies in size and shape.  Gap junctions often occur between the muscle arms of different muscle 
cells, coupling them electrically. 
Because of the many similarities between C. elegans body-wall muscle and the skeletal 
muscle of humans, as well as the numerous advantages of working with C. elegans, we have 
developed C. elegans as a model for studying muscle protein degradation.  I will discuss the tools 
we have designed toward this goal in the following section. 
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1.3.2 Tools for studying muscle in C. elegans 
By using the expression of muscle-specific reporter proteins in C. elegans, we are able to 
analyze muscle protein degradation in a genetically tractable organism that is amenable to RNAi 
and drug treatments.  In this study I will make use of three different reporter constructs and several 
different RNAi and drug treatments, as described below. 
 
Reporter Constructs 
The first of the three constructs is a chimeric protein consisting of the N-terminal 298 
amino acids of MHC (UNC-54) fused to B-galactosidase from Escherichia coli.  This chimeric 
protein is encoded by a transgene expressed from the muscle-specific MHC promoter and 
integrated on chromosome V [74].  Expression of the transgene is confined to the 95 body-wall 
muscles and eight vulval muscles [74].  Muscle in which the transgene is expressed accumulate 
the fusion product from embryogenesis through adulthood [74]. This myosin::lacZ fusion is 
tetrameric, soluble, and stable over at least 2.5 days [74].  When its degradation is induced, its 
degradation corresponds with its inactivation [74] and occurs at the same rate as native muscle 
proteins [75].  Therefore, we can use the activity of B-galactosidase in muscle to assay the extent 
and location of protein degradation in body-wall muscle of individual worms. The second 
construct is under control of the myo-3 promoter and expresses soluble GFP in body-wall muscle.  
Both of these reporters are degraded under conditions of starvation [74], denervation [71], 
excessive FGFR signaling [76], and deficient signaling through the IGFR [77].  Interestingly, the 
opposed FGFR and IGFR pathways interact directly at the level of the Raf-MEK-MAPK cascade, 
with FGFR signal promoting activating phosphorylation of Raf and IGFR signal resulting in 
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(AKT-1, AKT-2) 
Figure 4 
Signaling network regulating muscle protein degradation in C. elegans.  FGFR signaling 
promotes muscle protein degradation through activation of the Raf-MEK-MAPK cascade.  
IGFR signaling inhibits degradation through inhibition of the Raf-MEK-MAPK cascade.  In 
parentheses is the C. elegans nomenclature for the mammalian protein names. 
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inhibitory phosphorylation of Raf via Akt (Figure 4) [77].  FGFR and IGFR signaling and their 
integration at RAF will be reviewed in sections 1.3.3 and 1.3.4. 
Here, by applying the third construct, GFP-tagged LGG-1, I demonstrate that this signaling 
network regulates protein degradation through autophagy.  This construct takes advantage of the 
evolutionary conservation of the autophagic pathway through yeast, worms, and humans [59].  
LGG-1 is the worm ortholog of yeast Atg8/Aut7p and mammalian MAP-LC3.  LGG-1 localizes 
to pre-autophagosomal and autophagosomal membranes [78], as discussed in section 1.2.2, as well 
as the SR and the hypodermis. 
 
RNAi 
In C. elegans, introduction of dsRNA with the same sequence as a target endogenous gene 
results in interference with the function of that endogenous gene [79].  When dsRNA enters the 
cells, it is cleaved by Dicer into fragments of approximately 22 nucleotides in length [80].  These 
fragments associate with the RISC complex and one of the strands of the dsRNA is degraded [80].  
The remaining strand and RISC then bind to the complementary mRNA produced from the target 
gene, resulting in cleavage of the mRNA and prevention of translation [80].  This process is termed 
RNA interference (RNAi) and often phenocopies a strong loss-of-function mutation of the target 
gene [80]. 
 dsRNA can be introduced to C. elegans in multiple ways: by injection, soaking, or feeding 
[81].  RNAi by soaking and injection produce less variable results, but are more labor intensive 
[81].  For this study, I have used feeding of the worms with bacteria producing the dsRNA as my 
method.  RNAi by feeding is most effective in adults and against non-neuronal targets [82].  After 
ingestion, the dsRNA is taken up from the environment into the intestinal lumen through SID-1, a 
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transmembrane protein [83].  The silencing signal is amplified and spreads throughout the 
organism [83].  Amplification occurs through the action of RNA-dependent RNA polymerases, 
which generate 5’ triphosphate antisense RNAs [83].  Spreading of the signal is thought to occur 
in a SID-1 independent manner and the silencing signal is thought to be a longer dsRNA [83].  In 
C. elegans, the RNAi signal is also persistent.  It persists both in the animal exposed to the dsRNA 
and through multiple generations, albeit with reduced penetrance [83]. 
 
 
Drug Treatment 
 Drug treatment of C. elegans is used for drug screening and for basic biological research.  
Methods of applying drugs to C. elegans vary.  They include adding drugs to live or dead bacterial 
cultures that will be used for feeding and spotting of drugs directly on plates that are spread with 
live or dead bacteria [84].  Dead bacteria are sometimes used to eliminate the possibility the 
bacteria will degrade the drug and effectively reduce the concentration.  One study [84] that tested 
the absorption of a water-soluble and a minimally water-soluble drug found that both drugs 
reached considerable concentrations in the worms regardless of whether the drugs were added to 
the bacterial culture or spotted on the plate.  Addition of the drug to the bacterial culture was 
slightly more effective, however, the small increase in effectiveness may not balance the expense 
of this method requiring the use of more total compound.  Both the water-soluble and minimally 
water-soluble compound reached maximum concentration in the worms between 12 and 24 hours.  
For my studies, I use the cost-effective strategy of spotting drugs directly on plates spread with 
live bacteria.   
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 Two drugs used in my work are LY29004 and N6,N6-dimethyladenosine (DMA).  
LY29004 is a PI3K inhibitor.  There are three classes of PI3K, all of which are inhibited by 
LY29004, a synthetic compound based on the flavonoid quercetin [85].  LY29004 binds the ATP-
binding site of PI3K with an IC50 of 1.4 µM and a Kd of 0.21 µM [85].  Although this Kd is similar 
to that of less specific protein kinase inhibitors for PI3K, LY29004 is specific for PI3Ks, and at a 
concentration of 50uM has no inhibitory effect in vitro on other protein kinases that have been 
tested [85]. 
 DMA is an adenosine analog that has been shown to inhibit autophagic vesicle formation, 
possibly through the inhibition of a PI3K (see section 1.2.2 for the role of PI3K in autophagic 
vesicle formation) [86].  Inhibition of autophagy by adenosine analogs is rationalized as a negative 
feedback mechanism for the degradation of ribosomes and ribosomal RNAs by autophagy [86]. 
1.3.3 FGFR signaling  
Fibroblast growth factor receptors (FGFRs) are members of the receptor tyrosine kinase 
family [87].  In mammals, there are four FGFRs (1-4), each consisting of an extracellular, ligand-
binding domain, a transmembrane helix domain, and a cytoplasmic, tyrosine kinase domain [88].  
Combinatorial alternative-splicing yields FGFR that can vary structurally in each of the three 
domains [89].  The different FGFRs and their splice forms have varying affinities for, and 
responsiveness to, the more than 20 different FGFs [89].  Upon binding of FGF, activation of the 
FGFR kinase domain requires dimerization and trans-phosphorylation, which is promoted by 
association with heparan sulfate proteoglycans in a 2:2:2 or 2:2:1 FGF:FGFR:heparin ratio [89, 
90] or with the co-receptor Klotho [91].  Different splice forms of the FGFR can heterodimerize, 
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altering the activity of the complex [89].  This, in combination with the varying tissue-specific 
expression patterns, ligand affinities, and responsiveness of each receptor, allows one signaling 
system to control many distinct cellular and developmental processes [89].   
The 24 identified FGFs in mammals [92] can have either endocrine or paracrine function 
[91].  Paracrine FGFs function in patterning during development and in homeostatic processes in 
adult organisms [91]. Paracrine FGFs are characterized as having a high affinity for cell-surface 
heparan sulfate proteoglycans and sharing a β-trefoil structure, consisting of 12 anti-parallel β-
strands, and variable-length N- and C-terminal tails [92]. Regions of the trefoil bind to heparin 
[92], while other regions of the trefoil bind the FGFR [87].  Binding of heparan sulfate 
proteoglycans is required for high-affinity binding FGF to the FGFR [92].  The N- and C-terminal 
tails provide ligand-receptor specificity [92].  Upon secretion, paracrine FGFs bind cell-surface 
heparan sulfate proteoglycans, limiting their diffusion, protecting them from proteolysis, and 
promoting efficient signal transduction [87].  Due to these characteristics, during development 
paracrine FGFs are often found to pattern the tissue immediately surrounding their source [87].   
Endocrine FGFs have a low affinity for heparan and FGFR, and therefore are free to diffuse 
away from their source, enter the circulation, and induce signaling in other tissues [91].  Endocrine 
FGFs are often involved in metabolic processes, such as glucose and lipid metabolism, and depend 
on Klotho co-receptors to activate their FGFRs [91].  Klotho co-receptors are expressed in targets 
of endocrine FGFs and increase the affinity of the FGFR for endocrine FGFs, while simultaneously 
decreasing the affinity of FGFR for paracrine FGFs  [91].  This safe-guards against off-target 
signaling and prevents interference by paracrine FGFs [91] 
C. elegans has two FGF homologues, EGL-17 and LET-756, and one FGFR, EGL-15 [93].  
EGL-15 is structurally similar to vertebrate FGFR [87] and comparative modeling studies suggests 
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a conserved binding surface for heparin on the C. elegans FGF-FGFR complex [93].  Additionally, 
two redundant homologues of the Klotho co-receptor also are present in C. elegans and have been 
shown to play a role in EGL-17/EGL-15 signaling [94].  However, EGL-17 is not homologous to 
mammalian endocrine FGFs.  In fact, both EGL-17 and LET-756 are homologous to mammalian 
paracrine FGFs, albeit to FGFs in different subfamilies (FGF8 and FGF9 subfamilies, respectively) 
[95].  This suggests that the details of paracrine and endocrine FGF signaling as described in 
mammals cannot be mapped directly onto FGF signaling in C. elegans.   
The two C. elegans FGF ligands signal non-redundantly through distinct splice forms of 
the FGFR.  EGL-17 is secreted by the developing vulva and mutation of EGL-17 leads to abnormal 
sex myoblast migration and an egg-laying defect [96].  LET-756 is expressed by the body-wall 
muscle and various neurons [96].  Total loss-of-function mutation in LET-756 is lethal, while 
reduction-of-function mutation causes a scrawny phenotype [96].  It is thought the LET-756 signal 
from muscle binds hypodermal EGL-15 and regulates fluid balance [96].  EGL-17 and LET-756 
both have roles in axon growth and positioning, but of a non-overlapping subset of neurons [96]. 
Fibroblast growth factor signaling has been linked to exercise-induced muscle remodeling 
in rats, with exercise inducing increased FGF expression [97] and degradation of soluble and 
myofibrillar proteins in skeletal muscle [98].  These non-developmental roles for FGF signaling 
are interesting, since it was initially thought that FGFRs were not expressed in adult mammalian 
skeletal muscle.  Thinking has since changed [76]. 
In C. elegans, activation of the FGFR by temperature-sensitive (ts) inactivation of its 
phosphatase, CLR-1, promotes degradation of the unc-54::lacZ reporter.  This effect does not 
depend on new protein synthesis, since treatment with cycloheximide six hours prior to 
temperature shift does not prevent degradation.  While reduction-of-function (rf) in the kinase 
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domain of the FGFR does suppress the protein degradation phenotype of clr-1 mutants, rf mutation 
of either of the two FGF ligands present in C. elegans is not sufficient to suppress protein 
degradation, since in this case the two ligands are redundant.  As expected then, at least one of the 
FGF ligands is necessary for the protein degradation caused by rf mutation of clr-1.  [76] 
Ras (LET-60) GTPase is known to have a role in muscle wasting and a ts Ras gain-of-
function (gf), mutation promotes reporter degradation at the non-permissive temperature and has 
a clear (Clr) phenotype [76].  Likewise, rf mutation in the gene for the Ras GTPase-activating 
protein GAP-1 also promotes degradation of the reporter protein.  [99]  
In order to determine if activated Ras causes protein degradation through changes in de 
novo gene expression, ts Ras gf mutants were treated with cycloheximide to prevent translation.  
Treatment with cycloheximide did not block Ras-induced protein degradation, even when the 
cycloheximide treatment proceeded the temperature shift by six hours.  This shows that the 
degradation induced by Ras does not require the synthesis of new protein and therefore is unlikely 
to be due to gene expression changes induced by Ras activation. [99] 
The effect of Ras on muscle protein degradation was shown to be physiological, rather than 
developmental.  Animals raised for part of their development at the non-permissive temperature 
and then shifted to the permissive temperature retain LacZ staining in adulthood, while animals 
raised at the permissive temperature and then shifted to the non-permissive temperature as adults 
degraded protein.  This distinction between development and acute effects of protein activation 
will become important in the work I will discuss in the Results and Discussion. [99] 
These data are consistent with the idea that the FGFR is signaling through Ras to promote 
muscle protein degradation.  Treatment of ts Ras rf mutants with Ras inhibitor suppresses protein 
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degradation seen in clr-1 ts mutants.  Further experiments show that the FGFR signals to Ras 
through the C. elegans GRB2 and SOS1 homologs. 
Since Raf, MEK, and MAPK (C. elegans LIN-45, MEK-2, and MPK-1, respectively) had 
been shown to be downstream of Ras in the development of the hypodermis in C. elegans and the 
Clr phenotype is due to defective FGF signaling in the hypodermis, Szewczyk et al. sought to 
identify if Raf, MEK, and MAPK are also downstream of Ras in signaling for muscle protein 
degradation.  To do so, ts Ras gf mutation was combined with an additional rf mutation in Raf, 
MEK, or MAPK.  Muscle protein degradation was prevented in each of the double mutants, 
showing that Raf, MEK, and MAPK act downstream of Ras [99].  Likewise, ts clr-1 rf mutants with 
a second rf mutation in the gene coding for any member of the Raf-MEK-MAPK cascade show 
suppression of protein degradation at the non-permissive temperature, while Raf or MAPK 
activation is sufficient to induce degradation [77]. 
It should be noted that the outcome of this pathway is promotion of muscle protein 
degradation.  Since one of the FGF ligands is autocrine, it would seem as if the cell is constantly 
telling itself to degrade protein.  Indeed, this would be the case, if it weren’t for an additional, 
inhibitory input to the pathway, which I will discuss in the next section.  
1.3.4 IGFR signaling and Raf as a signaling integrator 
In mammalian muscle, insulin signaling has a well-known role in promoting protein 
accumulation and preventing its degradation.  Absence of insulin, as seen in Type I diabetics, 
causes increased skeletal muscle protein degradation and leads to muscle wasting [36].  Most well-
controlled studies show that insulin inhibits protein breakdown, but has little effect on protein 
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synthesis [36].  Likewise, systemic administration of insulin-like growth factor (IGF) inhibits 
whole body protein breakdown, but has no effect on whole body protein synthesis [36].  Insulin 
signaling and IGF signaling have both been shown to target skeletal muscle, although their 
downstream effects are not identical.  IGF signaling is associated with growth, differentiation, and 
hypertrophy, while insulin signaling is involved with metabolic processes [100].  Insulin is 
produced by pancreatic beta cells, while IGF-1 is produced by many different cell types [101]. 
Most of the circulating IGF-1 is produced by hepatocytes [101].   
Despite these differences, IGFs are structurally similar to insulin.  Human IGF-1 is 
composed of an alpha and beta chain linked by a disulfide bond, much like insulin [102].  The 
IGF-1 receptor and the insulin receptor are also structurally similar.  Both are disulfide linked 
homodimers, and IGF-1 receptor/insulin receptor heterodimers can form [103].  Both the IGF-1 
receptor and the insulin receptor can bind both IGF-1 and insulin, although with different affinities 
[103].  Binding of the ligand to the receptor results in formation of the tetrameric receptor, tyrosine 
phosphorylation, and activation of downstream pathways [100].  Additionally, IGF-1 receptors 
and insulin receptors require heterotrimerization with G-proteins for some of their biological 
effects [100].  The partially non-overlapping effects of IGF-1 and insulin signaling are thought to 
be caused by the different affinities with which they bind each receptor [100]. 
 In C. elegans, there is an insulin-like signaling pathway that has been shown to have a role 
in regulating proteolysis in muscle.  C. elegans has 38 insulin-like genes expressed throughout the 
body [101], but only has one receptor homologous to human insulin/insulin-like growth factor 
receptor (IGFR), daf-2 [104].  Insulin signaling might be paracrine, autocrine, and/or endocrine in 
C. elegans [101].  Temperature-sensitive, rf mutation in daf-2 (IGFR) promotes muscle protein 
degradation at the non-permissive temperature.  This effect is seen in adult worms after 
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temperature shift, is not suppressed by cycloheximide treatment, and can be suppressed by muscle-
specific expression of wt daf-2. [77] 
AGE-1 (PI3K), PDK-1, and AKT-1 or AKT-2 are the proteins canonically found 
downstream of IGFR.  Rf mutation in age-1 or treatment with a PI3K inhibitor phenocopies the 
daf-2 rf mutation.  PI3K produces PIP3, stimulating activity of PDK and AKT.  Gain-of-function 
mutation in PDK-1 or AKT-1 suppresses degradation caused by daf-2 ts mutation. [77] 
IGFR signaling negatively regulates activation of the Raf-MEK-MAPK cascade.  
Reduction-of-function mutation in Raf, MEK, or MAPK are each sufficient to block degradation 
in daf-2 ts mutants or LY29004-treated animals.  On the other hand, rf mutation in pathway 
members upstream of Raf does not.  This suggests that Raf may be the direct target of Akt.  
Mutation of a putative Akt phosphorylation site on Raf, S259 (mammalian numbering throughout), 
to alanine promotes muscle protein degradation [77].  In mammalian systems, phosphorylation of 
S259 inhibits Raf activity and inhibition of the phosphatases responsible for de-phosphorylation 
of S259 results in Raf that cannot be activated [105].  Raf activation requires phosphorylation of 
T491 and S494 [106], which may occur via trans-autophosphorylation after recruitment to the 
plasma membrane and oligomerization [107].  The propensity of any Raf molecule to become 
active is modulated by the phosphorylation state of its other regulatory sites, including S259 [105, 
108-111].  Therefore, signals from multiple sources result in Raf molecules with different 
phosphorylation profiles and which have different levels of activity.  This allows Raf to integrate 
signals from multiple inputs and provide the appropriate output. 
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1.4 CALCIUM SIGNALING IN MUSCLE 
In chapter 2.0, I will propose an additional positive input to the FGF/IGFR network I have 
described—specifically, from calcium signaling, through CaMKII.  High intracellular calcium is 
seen under conditions that cause atrophy, such as sepsis, burn injury, and muscular dystrophy [43, 
112].  Treatment with calcium ionophore increases muscle protein degradation, while treatment 
with calcium antagonists can inhibit it [43].  CaMKII acts as a calcium sensor and decodes calcium 
frequency-dependent information.  CaMKII itself is up-regulated during atrophy [113].  In this 
section, I will consider the known role of calcium in promoting muscle atrophy, the mechanisms 
by which calcium enters the cell, and the cellular behaviors stimulated by calcium influx. 
1.4.1 Calcium and muscle wasting 
The breakdown of muscle protein seen with trauma, burn, and sepsis can be beneficial.  
Amino acids released from the muscle are used by the liver for gluconeogenesis and the production 
of acute phase proteins [43].  Acute phase proteins are the liver’s response to post-injury 
inflammatory signals, and include proteins involved in fighting microbes, giving negative 
feedback to the inflammatory response, and promoting coagulation.  Glutamine, specifically, is 
used by cells in the immune system and can protect the intestinal mucosa in the critically ill [43].  
However, extensive muscle wasting is associated with poor clinical outcomes [43].   
Levels of calcium in skeletal muscle have been shown to be increased in various conditions 
that result in muscle wasting [43].  This alteration of calcium homeostasis can lead to, or 
exacerbate, tissue dysfunction caused by acute injury, such as trauma, burn, and sepsis [114].  
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Dysfunction can be caused by impairment of functions in resting cells or in cellular behaviors 
requiring calcium, such as contraction, secretion, signaling, etc. [114].  In the resting state, the 
concentration of calcium inside the cell is 40-100 nmol/L [114].  This is 10000 times less than the 
concentration of calcium outside the cell [114].  This gradient is maintained by constant extrusion 
of calcium from the cell into the extracellular space [114].  When stimulated, the calcium 
concentration in the cell can rise to 150-1,000 nmol/L [114].  This increase is caused by influx of 
calcium through voltage-gated or ligand-gated calcium channels and/or release of calcium from 
ER stores.   
Cytosolic calcium levels in septic muscle have been shown to be twice as high as normal 
[115, 116].  This increase in intracellular calcium promotes loss of muscle mass through activation 
of calcium sensitive proteases (calpains) and caspases (discussed in section 1.4.3), glucose-uptake 
insulin resistance [114], increased proteasome activity, apoptosis, and transcriptional changes [43].  
It is thought that high intracellular calcium can be caused by glucocorticoid signaling.  
Inhibitors of glucocorticoid receptors can block muscle wasting with sepsis and treatment with 
glucocorticoids can increase muscle protein breakdown [43].  Glucocorticoid treatment increases 
cytoplasmic calcium levels and calcium chelator can block the protein-degradative effects of 
synthetic glucocorticoid treatment [43].  While it is unknown exactly how glucocorticoid signaling 
increases cytosolic calcium levels, there is evidence that the calcium is not from extracellular 
sources, suggesting that increased calcium release from the SR may play a role [43].   
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1.4.2 Calcium channels in muscle 
Most calcium enters the muscle cell from the extracellular space through a voltage-gated 
calcium channel [117].  Historically, calcium channels have been classified by the voltage at which 
they open [118, 119].  There is one type of low-voltage calcium channel, T-type, while there are 
four types of high-voltage calcium channels (L-, N-, P/Q, and R) [119].  C. elegans has three multi-
subunit, voltage-gated calcium channels.  Each channel is defined by the gene coding the alpha 
subunit.  C. elegans  has the L-type channel, encoded by egl-19, the P/Q type channel, encoded by 
unc-2, and the T-type channel, encoded by cca-1 [117].  Although the P/Q type channel may also 
be expressed in body-wall muscle [120], the L-type calcium channel is considered the main 
voltage-gated calcium channel in body-wall muscle.  The L-type channel is also the most relevant 
channel in vertebrate muscle, so I will restrict my discussion to this channel type.  
The L-type calcium channel is a heteropentamer of α1 (EGL-19), α2, β, γ, and δ subunits 
[119].  The α1 subunit is composed of four transmembrane domains, each composed of six alpha 
helices, similar to the structure of sodium channels [119].  It is believed that the α1 subunit is 
responsible for voltage sensing [119].  The α1 subunit is sufficient for permeation to calcium ions; 
however, the remaining subunits have important modulatory effects [119].  
 In fact, behavior of the calcium channel is not only modulated by the additional subunits, 
but also by diverse signaling events.  Calmodulin, a calcium effector discussed in the following 
section, has been shown to bind and negatively modulate the L-type calcium channel, providing a 
feedback mechanism.  Phosphorylation of the α1 subunit by various signaling pathways has been 
shown to affect the calcium current.  The β subunit (CCB-1 in worms), which has been implicated 
in both trafficking and altering the biophysical properties of the alpha subunit, can be modulated 
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by phosphorylation by PKA, CaMKII, and Akt.  Interestingly, it has been shown in zebrafish that 
a specific β subunit, β1a, is required in muscle for tetrad formation with the RyR and normal 
movement.   [121] 
 
1.4.3 Calcium effectors 
Calmodulin 
Calmodulin is a relatively small protein of only about 150 amino acids with two N-terminal 
EF hands and two C-terminal EF hands linked by a flexible alpha helix [122].  Each EF hand is 
capable of binding one calcium ion [122].  The EF hands at each end have cooperative binding, 
such that both calcium sites are likely to be occupied [123].  The N- and C-terminal domains are 
not mirrors of each other; each has its own ion affinities and kinetics [123].  At resting membrane 
potential, when calcium concentration is low, a large fraction of calmodulin molecules have two 
calcium ions bound [123].  Since most of calcium-calmodulin’s downstream substrates require all 
of calmodulin’s sites to be occupied in order to bind, this form of calmodulin is inactive  [123].  
When the membrane is depolarized and calcium levels rise, all four sites bind calcium and 
calmodulin becomes active [122].  Activated calcium-calmodulin can interact with its several 
hundred target proteins [123].  Modeling of the dynamics of calmodulin activation suggest that 
these dynamics alone are sufficient for calmodulin to decode calcium spike timing for the 
activation specific targets [123].   
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Calpains and Caspases 
There are many different calpains, some of which are ubiquitous and others of which have 
tissue-specific expression [43].  Calpains are often heterodimers, with one subunit containing the 
catalytic domain and the other having regulatory functions [124]. Calcium-activated calpain is 
inhibited by two negative feedback mechanisms: 1) binding of an inhibitor, calpastatin, and 2) 
autolysis  [43].  There is also some positive feedback, in that activated calpain is capable of 
degrading its inhibitor, calpastatin [124].  C. elegans has genes encoding multiple calpains, 
although it lacks the calpain inhibitor, calpastatin [125] 
Calpains have been implicated in causing some of the protein degradation seen in sepsis 
and other muscle-wasting conditions [43].  Expression of calpain genes increases with sepsis; 
calpastatin expression decreases with sepsis; calcium is required for the release of myofilaments 
[126].  The last of these is an important point, as it has been shown that the proteasome is incapable 
of degrading intact myofilaments, suggesting that calpains may have a role in releasing 
myofilaments so that they may be accessed by the proteasome [126] . 
Others have suggested a role for caspase-3 in releasing myofilaments [127].  Caspases are 
cysteine-dependent aspartic-directed zymogens [128] that are categorized as either initiator or 
executioner caspases [129].  Upon cleavage, initiator caspases cleave executioner caspases, 
activating them [129].  C. elegans has four caspase genes [130].  Insulin resistance, which occurs 
during sepsis, has been shown to activate caspase-3 [127].  It is not entirely understood if high 
calcium can also contribute to glucose-uptake insulin resistance, since calcium signaling can be 
shown to both promote and inhibit production of the glucose transporter, GLUT4; however, insulin 
resistance has been shown to accelerate muscle protein degradation [131]. 
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The role of calpains and caspases in myofilament release for protein degradation by the 
proteasome becomes more complicated when one considers the possibility of cross-talk between 
the two systems.  Caspases have been shown to degrade calpastatin, which would promote 
activation of calpains, while inhibition of calpains by overexpression of calpastatin has been shown 
to up-regulate caspase-3 activity [132].   
1.4.4 Downstream calcium signaling through CaMKII  
CaMKII acts as a calcium sensor and decodes calcium frequency-dependent information.  
CaMKII itself is up-regulated during atrophy [113].  CaMKII, product of the C. elegans unc-43 
gene, is central in the cell’s ability to respond to calcium levels.  The CaMKII holoenzyme is a 
dodecamer composed of two face-to-face rings of six monomers.  Each CaMKII monomer consists 
of a kinase domain, a regulatory domain, and an association domain.  The association domain 
binds to the association domains of other monomers to assemble into the dodecameric 
holoenzyme.  The regulatory domain can act in an autoinhibitory fashion, by binding the kinase 
domain of CaMKII, or can act as the Ca2+/Calmodulin (CaM) binding domain (Figure 5).  [133] 
Due to these characteristics of its structure, activation of CaMKII can either be Ca2+/CaM 
dependent or Ca2+/CaM independent [6].  During Ca2+/CaM dependent activation, Ca2+/CaM binds 
the regulatory domain, releasing autoinhibition of the kinase domain and exposing Thr 286 (human 
CaMKII numbering throughout) [134].  The exposed Thr 286 is then autophosphorylated by a 
Ca2+/CaM-activated adjacent subunit.  Phosphorylation of Thr 286 prevents rebinding of the 
regulatory domain to the kinase domain [135] and increases the affinity of Ca2+/CaM for CaMKII 
by 13,000-fold [136].  When Ca2+ concentration is high, phosphorylation of Thr 286 will occur 
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faster than its dephosphorylation, resulting in a holoenzyme that is phosphorylated on all of its Thr 
286 residues.  When this occurs, CaMKII activation becomes Ca2+/CaM independent, as even 
release of Ca2+/CaM will not allow for rebinding of the regulatory domain to the kinase domain.  
However, when Ca2+ levels are low, Thr 286 is dephosphorylated faster than activation can spread 
through the holoenzyme, maintaining the Ca2+/CaM dependence of activation.  I will discuss 
further details of CaMKII activation as they become relevant in the Results and Discussion. 
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Structure of CaMKII and its activation.  
CaMKII monomers have a kinase domain 
(yellow/tan), regulatory segment (grey), and 
association domain (blue).  Monomers assemble 
into two face-to-face rings of six, resulting in a 
dodecameric, spindle-like structure.  With a 
short calcium signal, calcium dependent 
activation of CaMKII is maintained, while with 
a long calcium signal, calcium-independent 
activation results.  Neighboring subunits 
phosphorylate each other, preventing re-binding 
of the autoinhibitory domain, contained in the 
regulatory segment.  Only a phosphatase, FEM-
2, can remove the phosphate group and restore 
calcium dependency. Adapted from Hudmon, 
2002 [4] and Lisman, 2002 [6]. 
Figure 5 
43 
 
2.0  RESULTS AND DISCUSSION 
Here I propose an additional input to the FGF/IGFR network—specifically, calcium 
signaling through CaMKII (UNC-43).  Employing a CaMKII gain-of-function (gf) mutant and a 
FEM-2 temperature-sensitive (ts), reduction-of-function (rf) mutant, I show that hyperactive 
CaMKII promotes protein degradation in C. elegans body-wall muscle through activation of the 
Raf-MEK-MAPK cascade.  I also propose an in vivo role for FEM-2 in C. elegans body-wall 
muscle in de-activating CaMKII.  I show that the FGF/IGFR/CaMKII signaling network described 
herein regulates protein degradation via autophagy.  Having detailed the network, questions about 
the behavior of the network as a whole can be addressed.  One such question I address is whether 
increases or decreases in signaling from one source can be balanced by increases or decreases in 
signaling from another.  This is a particularly interesting question in the network described here, 
where one protein, Raf, is responsible for integrating signals from multiple sources.    
2.1 CAMKII GF MUTATION RESULTS IN PROGRESSIVE MUSCLE PROTEIN 
DEGRADATION 
The CaMKII gf protein (CaMKII*) has an E108K substitution resulting from a missense 
mutation (allele n498) in the unc-43 gene [137].  This mutation likely prevents docking of the 
autoinhibitory domain on the kinase domain [138], causing constitutive activity independent of 
Ca2+/calmodulin (Figure 5).  unc-43 gf mutants do synthesize LacZ reporter protein in muscle 
during larval growth (Figure 6a), although delayed relative to wild type (wt). However, the LacZ 
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protein that they do accumulate is lost shortly after entry to adulthood (Figure 6a). This protein 
degradation is accompanied by the progressive development of uncoordinated movement (Figure 
7).   As expected for a gf mutation, both the uncoordinated movement and protein degradation 
phenotypes show partial dominance in unc-43gf/+ heterozygotes (data not shown).  Additionally, 
unc-43 gf worms are egg-retentive and frequently bag (embryos hatch internally).  In Figure 8, an 
internally hatched embryo is visible in the unc-43 gf worm.  Despite these phenotypes, the actin 
filaments appear intact and appropriately organized, as evidenced by Phalloidin staining (Figure 8).      
Fusion of the unc-43 promoter to gfp results in expression of GFP in the neurons, intestines, 
and body-wall muscle (Figure 9), consistent with the known neuronal [138, 139], intestinal [140], 
and muscular [138, 141] functions of CaMKII in C. elegans.  Since knowing the location(s) where 
CaMKII* activity is required for the phenotypes could provide clues about how CaMKII* is acting 
to cause the above phenotypes, I wanted to determine this information.  
To test if muscular CaMKII* is required for uncoordinated movement and protein 
degradation, I took advantage of the fact that in C. elegans RNAi is ineffective in neurons [82].  
Treatment of unc-43 gf mutants with unc-43 RNAi suppresses degradation of both LacZ and GFP 
reporter proteins (Figure 6b), but not the uncoordinated movement phenotype (data not shown) or 
the egg-laying defect (Figure 6b).  This shows that non-neuronal (likely muscular) CaMKII* is 
required to cause muscle protein degradation in muscle, while neuronal CaMKII* is sufficient to 
cause uncoordinated movement and the egg-laying defect.  From this, I hypothesized that the 
protein degradation caused by CaMKII* is the result of its signaling intramuscularly, while the 
uncoordinated movement may originate from problems in neuro-muscular communication.   
The unc-43 gf mutation causes life-long, chronic CaMKII hyper-activation, which is 
known to cause defects in axonal guidance and morphology [139, 142].  Coordinated movement 
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unc-43 gf worms degrade muscle protein, which can be suppressed by treatment with unc-43 RNAi.  a) unc-43 gf 
and wt worms were synchronized as L1s and raised at 20C.  Every 24 hours animals were selected from the 
population and stained for LacZ. b) L4 unc-43 gf worms were picked to unc-43 or null RNAi plates and raised at 
20C.  When the F1 reached adulthood, worms were selected for LacZ staining or GFP imaging.   
Figure 6 
CMF 
LAJ 
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unc-43 gf worms are uncoordinated. Adult unc-43 gf or wt worms were picked into buffer and their swimming 
rate was measured as strokes per minute.  unc-43 gf worms make fewer strokes per minute then wt worms due to 
their uncoordinated movement. n= 10 replicate measurement on 5 worms of each genotype.  The p-value was 
calculated using the students T-test. 
Figure 7 
47 
 
Figure 8 
Actin filaments of unc-43 gf worms do not appear disorganized.  Both wt and unc-43 gf worms were grown at 20C 
until adulthood, at which point individuals were selected for RITC-labeled Phalloidin staining of actin filaments.  
After staining overnight, images were collected via fluorescence microscopy.  Note the internally hatched embryo 
in the unc-43 gf worm.    
48 
 
Fusion of the unc-43 promoter to gfp results in GFP expression in muscle, neurons, and the intestine.  Worms 
expressing the unc-43::gfp fusion were grown at 20C until adulthood, at which point individuals were observed 
by fluorescence microscopy.   
Figure 9 
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and maintenance of muscle protein levels requires correct formation of the neuromuscular junction 
(NMJ) during development, maintenance of that junction during larval growth, and proper 
functioning of neuron and muscle post-development.  Defects in any of these can result in 
uncoordinated movement [143] and muscle protein degradation [71].  Thus, the phenotypes seen 
in unc-43 gf worms could be the result of developmental defects or post-developmental defects. 
In unc-43 gf worms, both the cell-specific pattern of LacZ staining and the timing of its 
loss are distinct from what is observed in genetically denervated animals [71], suggesting that 
NMJs develop, to some extent, functionally.  This is consistent with the observation that unc-43 
gf mutant larvae move quite well.  On the other hand, that neuronal CaMKII* is sufficient for 
progressively uncoordinated movement suggests that neuromuscular communication eventually 
becomes abnormal.  These developmental defects could mask the effect of muscular CaMKII* on 
movement.  Indeed, detailed analysis [138] of the movement defects seen in unc-43 gf and rf 
mutants show that their movement is characteristic of what would be expected if CaMKII has a 
role in movement both in neurons and muscles.   
I, therefore, sought to distinguish the roles of life-long (chronic) versus post-developmental  
(acute) hyperactivation of CaMKII in these phenotypes.  I hypothesized that post-developmental 
hyperactivation of CaMKII would cause muscle protein degradation and uncoordinated 
movement. 
 For acute activation of CaMKII, no temperature sensitive (ts) unc-43 gf mutant is 
available, so we used a fem-2ts rf mutant.  Research has shown that FEM-2 protein from C. elegans 
dephosphorylates C. elegans CaMKII [144] and human CaMKII [145] in vitro, causing its 
inactivation.  Therefore, at the non-permissive temperature, reduction of FEM-2 function should 
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increase CaMKII phosphorylation and activation and lead to phenotypes similar to those seen in 
unc-43 gf worms.   
At the non-permissive temperature, the fem-2ts rf mutation causes an increase in 
phosphorylated (p) T286-CaMKII (P-CaMKII) (Figure 12).  Figure 10a shows that fem-2ts rf 
mutants trigger muscle protein degradation upon shift to the non-permissive temperature (25C).  
Although both penetrance and expressivity of this phenotype is not 100%, there was a significantly 
greater frequency of individuals showing muscle protein degradation in the fem-2ts rf population 
compared to wt.  This degradation required muscular CaMKII, since pre-treatment with unc-43 
RNAi prevented degradation in the fem-2ts rf mutants (Figure 10b).   
fem-2ts worms also have uncoordinated movement.  Again, although there is variable 
penetrance and expressivity, there is a significantly greater frequency of individuals with 
uncoordinated movement in the fem-2ts population compared to wt (Figure 11).  Treatment of fem-
2ts worms with unc-43 RNAi reduced the frequency of individuals showing uncoordinated 
movement by swimming assay (Figure 11) and by head-tap response (data not shown)..  
These data show that muscular rather than neuronal CaMKII is responsible for the protein 
degradation seen both with chronic hyper-activation in unc-43 gf worms and with acute hyper-
activation in fem-2ts worms.  They also show that while chronic, neuronal hyper-activation of 
CaMKII is sufficient to produce uncoordinated movement, acute hyper-activation of CaMKII 
causes uncoordinated movement through the action of non-neuronal CaMKII.  
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CMF 
Figure 10 
 fem-2
ts 
rf  causes lacZ degradation, which can be suppressed by unc-43 RNAi treatment.  a) fem-2
ts 
rf worms were 
synchronized as L1s and grown to young-adulthood, at which point they were shifted to 25C for 48 hours.  498 
fem-2
ts 
rf and wt individuals were stained for lacZ and scored for extent of degradation, with 1 being maximal 
degradation and 5 being no degradation.  The distribution of protein degradation in each population was mapped 
in the above violin plot; the width of the violin represents the number of individuals with a particular protein 
degradation score, the top and bottom of the thick black line mark quartile 1 and quartile 3, respectively, and the 
white circle marks the mean.   The difference between the populations was calculated using the chi square test for 
independence. b) L4 fem-2
ts 
rf worms were picked to unc-43 or null RNAi and maintained at 16C.  When the F1 
reached young-adulthood, the were shifted to  25C.  After 48 hr they were stained for LacZ.  
ESO 
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p<0.001 
p<0.001 
p=0.02 
Figure 11 
fem-2
ts 
rf  causes lacZ uncoordinated movement, which can be suppressed by unc-43 RNAi treatment.   fem-2
ts 
rf
worms were synchronized as L1s and grown to young-adulthood on unc-43 or null RNAi, at which point they 
were shifted to 25C for 48 hours or kept at 20C.  fem-2
ts 
rf and wt individuals were picked into buffer and assayed 
for swimming rate. In the above violin plot, the width of the violin represents the number of individuals with a 
particular movement score, the top and bottom of the thick black lines mark quartile 1 and quartile 3, respectively, 
and the white circle marks the mean.  p-values were calculated using the Wilcox Rank Sum Test.  n= 5 replicate 
measurements for 2 worms of each category. Data, ESO.  Analysis, CMF. 
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2.2 CAMKII SIGNALS THROUGH RAF-MEK-MAPK TO PROMOTE MUSCLE 
PROTEIN DEGRADATION 
The protein degradation observed in unc-43 gf mutants is similar to that found in mutants 
with hyperactivity in the Raf-MEK-MAPK pathway [76, 77, 99]. This led to the hypothesis that 
CaMKII signaling might positively regulate the Raf-MEK-MAPK module.  
In order to determine if activation of the Raf-MEK-MAPK module is necessary for unc-43 
gf phenotypes, I made an unc-43gf; mpk-1 (MAPK) rf double mutant.  The mpk-1 rf mutation 
completely suppressed the unc-43 gf protein degradation phenotype, showing that CaMKII is 
acting upstream of MAPK (Figure 12a).  Thus, although CaMKII may have many cellular targets, 
its output via MAPK is uniquely required to stimulate protein degradation.  However, the 
movement defect seen in unc-43 gf animals was not suppressed in the unc-43 gf; mpk-1 rf double 
mutant, suggesting that the effect of chronic CaMKII hyperactivity on movement results from 
signaling independent of MAPK.  This does not eliminate the possibility that the movement defect 
caused by acute hyperactivation of CaMKII requires MAPK, although this is unlikely as activation 
of any protein in the Raf-MEK-MAPK module does not result in uncoordinated movement 
phenotypically similar to that observed in CaMKII gf mutants. 
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CMF 
Figure 12 
Degradation caused by hyperactive CaMKII requires MAPK and results in activation of Raf and MEK. a) wt, unc-
43 gf, and unc-43 gf; mpk-1 rf adults were raised to adulthood at 20C and then stained for LacZ.  (B) wt and unc-
43 null worms were synchronized and grown to adulthood, at which point western blot samples were collected.  
After blotting, primary antibody for human P-S621 Raf was used.  The weak signal was quantified using imageJ 
software.  (C) fem-2
ts
 rf worms were synchronized, grown to adulthood, and shifted to 25C or held at 15C for 48 
hours before collection for western blot samples.  All data shown above are from reprobes of the same blot.  
ESO 
CMF 
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We next sought to determine if CaMKII is also upstream of Raf.  Raf activation requires 
phosphorylation of T491 and S494 [106], which may occur via trans-autophosphorylation after 
recruitment to the plasma membrane and oligomerization [107].  The propensity of any Raf 
molecule to become active is modulated by the phosphorylation state of its other regulatory sites, 
specifically S259 and S621 [105, 108-111].  pS621 can be either stimulatory or inhibitory, 
depending on the context [146].  pS621, in the absence of pS259, stimulates Raf activation.   
Mammalian Raf S621 is predicted to be a CaMKII target [147].  The C. elegans homologue 
of Raf-1 is LIN-45.  Raf-1 S621 is analogous to LIN-45 S756.  Both sites match the CaMKII 
consensus target sequence rxxS/Txp (Table 1) and the lin-45 mutant allele ku112 is a weak LIN-
45 hypomorph [148].  (I will henceforth denote LIN-45 S756 as “S621” for compatibility with the 
mammalian Raf literature.)   
Table 1 Candidate CaMKII target sites 
Raf protein Sequence (S is target) 
hRaf-1 RSASEP 
hBRaf RSASEP 
LIN-45 RSQSAP 
LIN-45 ku1112 RFQSAP 
 
To determine if CaMKII is required for stimulatory phosphorylation of Raf S621, pS621 
Raf in wt and CaMKII null mutant animals was assayed.  CaMKII null mutants were generated 
and verified as described in the Methods section.  Null mutation of CaMKII reduced pS621-Raf 
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to a nearly undetectable level (Figure 12), showing that CaMKII likely acts directly upstream of 
Raf to phosphorylate S621.  
If CaMKII signals positively through Raf-MEK-MAPK, this implies that acute activation 
of CaMKII should result in increased activating phosphorylation of Raf, MEK, and MAPK.  To 
acutely activate CaMKII, the fem-2ts mutant was used.  It was found that increased pT286-CaMKII 
correlated with increased pT491/pS494 (active) Raf and P-MEK-2 (Figure 12c).  These 
observations confirm the genetic analysis.  
2.3 AUTOPHAGY IS REQUIRED FOR PROTEIN DEGRADATION INDUCED BY 
CAMKII SIGNALING  
The muscle protein degradation caused by activation of the Raf-MEK-MAPK cascade does 
not require the proteasome [99], in contrast to proteasome-dependent protein degradation caused 
by starvation and denervation [147]. Since the proteasome is not required for degradation induced 
by the Raf-MEK-MAPK cascade, it was hypothesized [77] that autophagy may be required.  To 
test this, animals expressing a constitutively active Drosophila MEK and a heat shock-inducible 
MAPK (resulting in high levels of active P-MAPK at 25C) were treated with autophagy inhibitors 
and then assayed for protein degradation by LacZ staining.  We inhibited autophagy in two ways: 
1) by RNAi knockdown of bec-1 or atg-7, which code for proteins involved in autophagic vesicle 
nucleation and elongation, respectively (see section 1.2.2), and 2) by rf mutation of the TOR-
responsive, atg-1 homologue, unc-51. Both measures suppressed protein degradation (Figure 13), 
as did treatment with the autophagy inhibitor DMA, showing that autophagy is required for 
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degradation induced by activation of the Raf-MEK-MAPK cascade (C. Bialas, A. Ayyash, L. 
Jacobson, unpublished).  
Since CaMKII requires MAPK to signal for protein degradation, I tested if unc-43 gf 
worms have an increase in autophagy and if autophagy is required for protein degradation.  To 
assay autophagy in unc-43 gf worms, an unc-43 gf mutant that expresses a GFP::LGG-1 fusion 
was constructed.  LGG-1 is the C. elegans ortholog of yeast Atg8/Aut7p and mammalian MAP-
LC3 [59].  Both of these LGG-1 orthologs localize to pre-autophagosomal and autophagosomal 
membranes, and, notably, the SR [78]. Our construct labels these vesicles in all cells of the unc-
43 gf mutant. The depth of focus of the confocal microscope I used for imaging these worms is 
approximately equal to the depth of the muscle belly of the body-wall muscle cells.  Therefore, I 
collected one optical slice for each sample and quantified the number of autophagic vesicles in 
that slice by counting the number of autophagic vesicles per muscle area.     Figure 14 shows 
confocal pictures of wt and unc-43 gf worms.  Note the larger number of vesicles in the body-wall 
muscle of the unc-43 gf worm.  
Wild type worms have a basal number of autophagic vesicles in muscle, which increases 
between 24 and 48 hours post-L4 (Figure 15a).  This level remains constant until 72 hours post-
L4.  On the other hand, unc-43 gf mutants initially have a three-fold higher number of autophagic 
vesicles and these numbers continue to increase through to 72 hours post-L4 (and possibly beyond) 
(Figure 15a).  The increase in the number of autophagic vesicles in wt worms between 24 and 48 
hours may be a feature of aging.  Although the worm lifespan is 12-18 days, worm muscle starts 
showing aging-related changes as early 7 days after hatching [149].  It is not surprising, then, that 
autophagy, which has been shown to be required for extended lifespan under multiple conditions 
and the inactivation of which accelerates aging of tissues in C. elegans [150] should be up-
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Figure 13 
Inhibition of autophagy suppresses muscle protein degradation in hyperactive MAPK worms.  Animals were 
age-synchronized and plated on either bec-1, atg-7, or null RNAi plates and grown to mid-adulthood before heat-
shock and shift to 25C.  Alternatively, unc-51 rf double mutants were grown to mid-adulthood before heat-shock 
and shift to 25C.  Individuals were then stained for beta-galactosidase activity. 
LAJ 
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   Figure 14 
Muscle cells 
Muscle cells 
unc-43 gf worms have more LGG-1 positive autophagic vesicles than wt.  L4 unc-43 and wt 
worms were picked to fresh plates and grown at 20C for 24 hours before imaging.  Confocal 
microscopy was used to collect images of the muscle belly, as described in Materials and 
Methods. 
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Figure 15 
unc-43 gf worms have increased numbers of autophagic vesicles compared to wt, which can be suppressed by unc-
43 RNAi treatment.  a) L4 unc-43 gf and wt worms were picked to fresh plates and then analyzed every 24 hours 
for the number of autophagic vesicles present in the muscle cells.  At 24 hr, n=14 worms.  At 48 hr, n=17.  At 72 
hr, n=18.  b) L4 unc-43 or wt worms were picked to unc-43 or null RNAi plates.  When the F1 reached L4, they 
were picked to fresh plates and were analyzed for the number of autophagic vesicles 24 hours later.  For wt, n=26.  
For unc-43 worms, n=21.  In all cases, the worms were photographed under the confocal microscope with several 
muscle cells in the field of view.  For each individual worm photographed, the highest quality image was selected 
for quantification.  During quantification, all autophagic vesicles in muscle cells and in the focal plane were 
counted.  p-values were calculated using the Student’s T-test.   
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regulated as early as 5 days after hatching (48 hours post-L4).  It could be interesting to follow 
lifespan and number of autophagic vesicles in the mutants described here.   
Subsequent experiments to compare number of autophagic vesicles to wt were done at 24 hours 
post-L4 to reduce aging-related complications.    
The high number of autophagic vesicles seen in unc-43 gf worms can be suppressed by 
unc-43 RNAi treatment (Figure 15b). This shows that it is the non-neuronal activity of CaMKII, 
likely in the muscle, which causes the increase in autophagic vesicles.  This is consistent with the 
data in Figure 6b showing that protein degradation is caused by non-neuronal activity of CaMKII.   
Note that even the basal number of autophagic vesicles in wt worms is further reduced by 
treatment with unc-43 RNAi (Figure 15b).  Studies by Shephard et al. have shown that multi-
generational unc-43 RNAi treatment causes defects in myofibril and mitochondrial maintenance 
[151].  Autophagy is known to be required for maintenance of muscle mass and for prevention of 
atrophy and myopathy, likely due to the role of autophagy in clearing damaged proteins and 
organelles [50, 58].   These data suggest that knockdown of CaMKII (unc-43) inhibits basal 
autophagy and thereby might be preventing the normal recycling of used and damaged cellular 
components leading to myopathy.  In light of the autophagy data presented for wt animals above, 
it could likewise be interesting to look at any aging effects of unc-43 RNAi treatment on aging of 
the muscle tissue.   
To test if autophagy is required for muscle protein degradation induced by CaMKII 
hyperactivity, I blocked autophagy in unc-43 gf mutants in two ways.  Either I introduced an 
additional unc-51 rf mutation into the unc-43 gf strain or I treated with the autophagy inhibitor 
DMA.  unc-51 rf mutation prevents protein degradation (Figure 16a) and treatment with DMA 
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Figure 16 
Inhibition of autophagy suppresses autophagic vesicle formation and muscle protein degradation in unc-43 gf 
worms.  a) Adult unc-43 gf or unc-43 gf; unc-51 rf worms were grown to adulthood and stained for LacZ.  b) unc-
43 gf worms were treated with DMSO or DMA and then picked to fresh plates as L4s and were analyzed for the 
number of autophagic vesicles 24 hours later.  19 worms were photographed and, based on quality, one image per 
worm was selected for quantification. 
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suppresses the higher level of autophagic vesicles normally seen in unc-43 gf individuals (Figure 
16b), demonstrating that autophagy is required for protein degradation in unc-43 gf worms.   
My observations, taken together with those of Shephard et al. [151], suggest that a basal 
level of autophagy in muscle is required for “housekeeping” functions, but that excessive 
autophagy, as seen in unc-43 gf worms, leads to pathologic levels of protein degradation. 
Protein degradation caused by acute increase in Raf-MEK-MAPK signaling or decreased 
IGFR signaling cannot be blocked by treatment with cycloheximide, a protein synthesis inhibitor 
[77, 99, 152], showing that degradation is not caused by the downstream effects of transcriptional 
changes, but by the activation of a pre-existing proteolytic system.  To verify that the autophagy 
caused by hyperactivity of CaMKII acts in a manner consistent with this hypothesis, fem-2ts worms 
were treated with cycloheximide, a protein synthesis inhibitor, and assayed to see if this could 
prevent any increases in autophagic vesicle formation at the non-permissive temperature.   
Interestingly, treatment with cycloheximide increased the number of autophagic vesicles 
both at the non-permissive and permissive temperature, well beyond anything we have observed 
with activation of the signaling network described here (Figure 17).  Other studies have shown 
[153] that cycloheximide blocks later stages of autophagy, causing accumulation of autophagic 
vesicles.  We have shown that treatment with cycloheximide does not block inactivation of LacZ 
when degradation is induced in by activation of Raf by temperature shift after six hours of pre-
incubation with cycloheximide [99].  Thus, our results suggests that whatever pre-existing proteins 
are required for autophagy have a longer life than six hours.  Theoretically, if we extended the pre-
treatment with cycloheximide, we should eventually prevent autophagy, although obvious 
complications arise with increased duration of cycloheximide treatment.  It should be remembered 
that degradation, as I have defined it here, is loss of LacZ activity.  “Degradation”, therefore, does 
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Figure 17 
Treatment with cycloheximide causes increased number of autophagic vesicles compared to untreated animals.  
As L4s, fem-2 ts worms were picked to plates containing 400 µg/mL cycloheximide and then were either kept 
at 16C or shifted to 25C.  After 48 hours, the number of autophagic vesicles were analyzed. At 15C, n=16 
worms.  At 25C, n=17 worms.  p-values were calculated using the Student’s T-test. 
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not necessarily represent full breakdown of the protein into its constituent amino acids.  Early 
stages of autophagy may be sufficient to cause inactivation of LacZ if vesicles are acidified and 
LacZ is denatured. 
As part of the above experiment I quantified the number of autophagic vesicles caused by 
acute CaMKII hyperactivation in fem-2ts worms.  After 48 hours at the non-permissive 
temperature, fem-2ts worms had a significant increase in the number of autophagic vesicles (Figure 
17).  However, due to the accelerated aging at higher temperature, this increase is likely age-
related.  Indeed, wt controls also show more vesicles after 48 hours at the non-permissive 
temperature compared to worms at the permissive temperature (data not shown). 
2.4 CAMKII SIGNALING COUNTERBALANCES IGFR SIGNALING 
Previous work on this signaling network has shown that signaling through the IGFR 
opposes FGFR signaling through inhibitory phosphorylation of Raf S259.  Thus, degradation 
caused by decreases in inhibitory IGFR signaling can be prevented by simultaneous decreases in 
stimulatory FGFR signaling [77].  Since signaling is also integrated into the network as a positive 
input at the level of Raf, I conjectured that increases or decreases in IGFR signaling could be 
balanced by increases or decreases in CaMKII signaling. 
Initially, I tested if protein degradation caused by decreases in IGFR signaling could be 
suppressed by decreases in CaMKII signaling.  I decreased signaling through the IGFR pathway 
in two ways.  First, I treated with the PI3K inhibitor, LY294002.  PI3K is downstream of IGFR 
and its inhibition promotes degradation [77].  Treatment of wt worms with LY294002 causes 
66 
 
muscle protein degradation, whereas CaMKII protein null mutants (Q67stop) do not degrade 
muscle protein when treated with LY294002 (Figure 18).  MEK is downstream of both PI3K and 
CaMKII.  Western blots show an increase in P-MEK-2 with LY294002 treatment in wt worms, 
but no such increase in CaMKII protein null worms treated with LY294002 (Figure 18b).  MEK-
1 is unresponsive. This is consistent with genetic evidence that MEK-2 is necessary for signaling 
between LIN-45 Raf and MPK-1 MAPK in C. elegans muscle [99]. 
I also made IGFR (daf-2ts), CaMKII (unc-43 rf) double mutants.  The daf-2ts single mutant 
degrades protein at the non-permissive temperature, but the double mutant does not (Figure 19a).  
Likewise, the daf-2ts mutant shows an increase in P-MAPK after shift to the non-permissive 
temperature, while the double mutant does not (Figure 19b).  
Lastly I tested the inverse possibility, to see if increases in IGFR signaling could balance 
the pro-degradative effect of increased CaMKII activity.  I increased signaling through the IGFR 
arm of the pathway by RNAi knockdown of daf-18.  DAF-18 is a PTEN-class lipid phosphatase 
that converts the PIP3 formed by active PI3K back to PIP2, thereby attenuating the signal.  
Knockdown of DAF-18 should thus increase the amount of PIP3 and promote IGFR signaling.  As 
predicted, unc-43 gf worms treated with daf-18 RNAi have a reduced number of autophagic 
vesicles relative to worms treated with null RNAi (Figure 20).  
The ability of Raf to integrate signals from the IGFR, FGFR, and CaMKII depends on the 
multiple phosphorylation sites that regulate its activation [154].  Signaling from the FGFR to Ras 
promotes localization to the plasma membrane, oligomerization, and activating phosphorylation  
of Raf [155].  The tendency of Raf to become active is controlled by phosphorylation of the 
inhibitory S259 site by AKT (downstream of IGFR) and phosphorylation of the stimulatory S621 
site by CaMKII (Figure 21).   
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Figure 18 
CaMKII null mutation prevents degradation caused by inhibition of IGFR signaling.  a) L4 wt and unc-43 null 
worms were picked as L4s to 160 uM LY-294002 or DMSO plates.  48 hours later they were a) stained for LacZ, 
or b) were collected for western blot samples with 30 worms/sample.  After blotting, the membrane was probed 
for P-MEK and then re-probed for actin. 
KAC 
CMF 
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Figure 19 
unc-43 rf mutation suppress protein degradation and increased P-MAPK caused by daf-2
ts
 rf mutation.  Animals 
were synchronized, grown to young-adulthood and shifted to 25C for 48 hr.  They were then stained for LacZ  (a) 
or picked for western blotting, with 30 worms/sample (b).  Note that the relevant LacZ stain is in the body-wall 
muscle, not in embryos seen in egg-retentive individuals (e.g., daf-2 at 25C).  The blot was probed for P-MAPK 
and re-probed for actin. 
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Figure 20 
daf-18 RNAi treatment reduces the number of autophagic vesicles in unc-43 gf worms.  L4 unc-43 gf worms were 
picked to daf-18 or null RNAi plates.  When the F1 reached the L4 stage, they were picked to fresh plates.  24 
hours later they were then analyzed for the number of autophagic vesicles. 20 worms were photographed and the 
highest quality image for each worm was selected for quantification. The p-value was calculated using the 
Student’s T-test. 
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Figure 21 
Raf activation.  Signaling from CaMKII promotes activation of Raf via phosphorylation of S621.  When Ras is 
active, Raf that is phosphorylated on S621 and dephosphorylated on S259 can localize to the plasma membrane, 
oligomerize, and become active by phosphorylation of T491/S494.  Signaling from the IGFR, via AKT, results 
in inhibitory phosphorylation of Raf at S259. 
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Raf pS621 is necessary to promote muscle protein degradation.  pS621 in the absence of 
pS259 (by LY294002 treatment or S259A mutation) causes protein degradation (Figure 18a and 
Figure 22, respectively). In the absence, or reduction, of CaMKII (and hence pS621), degradation 
cannot be stimulated by decreased IGFR signaling (Figure 18a) or by S259A mutation of Raf 
(Figure 22).  This is consistent with other studies showing that 14-3-3 binding to pS621 is required 
for activation of Raf [156].  
Raf pS621, however, is not sufficient to promote degradation.  In wt worms, both S621 and 
S259 are phosphorylated, leading only to basal levels of Raf activation (Figure 12c) and normal 
maintenance of muscle protein.  In this case, it is thought [157] that 14-3-3 binds to pS259/pS621 
Raf and prevents dimerization.  Figure 18 and Figure 22 similarly show that, in contrast to pS621, 
Raf pS259 is sufficient, but not necessary to inhibit muscle protein degradation. 
2.5 A ROLE FOR SPLICE FORMS? 
While the model of CaMKII activation described in Section 2.5 is useful for a basic 
understanding of CaMKII activation, the situation in vivo is much more complicated.  Information 
encoded by a calcium signal can vary based on its frequency, magnitude, duration, and tempero-
spatial localization [158].  CaMKII, as one of the interpreters of these varying signals, must be 
able to read and respond uniquely to each.  In mammals, one way that this is achieved is by the 
production of a family of CaMK enzymes, four of which are multifunctional (CaMKK, CaMKI, 
CaMKII, and CaMKIV).  CaMKK, CaMKI, and CaMKIV all function as monomers and can 
diffuse into the nucleus where they affect transcription.  CaMKK can be activated either by active 
hsp::lin-45 S259A hsp::lin-45 S259A; 
unc-43 rf 
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Figure 22 
Reduction-of-function mutation in unc-43 suppresses the protein degradation seen in Raf S259A mutants.  
Worms were age-synchronized and then heat-shocked for 30 min at 37C.  After the heat shock, they were 
shifted to 25C for 48 hours before LacZ staining.  
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PKA or Ca2+/CaM, depending on the isoform.  Once it is activated, CaMKK goes on to 
phosphorylate and activate CaMKI and CaMKIV.  CaMKI and CaMKIV require both activation 
by CaMKK and Ca2+/CaM to be active.  One of CaMKI and CaMKIV’s substrates is the nuclear 
localization signal (NLS) contained in certain splice variants of CaMKII.  Phosphorylation 
adjacent to the NLS prevents nuclear localization of these CaMKII isoforms [159].  
Of the multifunctional CaMKs, only CaMKII oligomerizes to form the dodecameric 
holoenzyme described above [160].   Human CaMKII includes four isoforms (alpha, gamma, beta, 
and delta) encoded by separate genes, and more than 20 splice variants of those isoforms [161].   
There is also a non-kinase variant, alpha-KAP, whose promoter is intronic to CaMKII and which 
contains an association domain similar to CaMKII’s, but lacks the kinase domain.  Different splice 
variants of alpha-KAP contain a nuclear localization signal and/or an N-terminal hydrophobic 
domain.  These splice variants localize to the nucleus or the SR membrane. [162]   
These different forms of CaMK are expressed in an array of combinations in a variety of 
tissues/cells at appropriate stages of development.  At the sub-cellular level, isoforms and splice 
variants can be differentially localized based on inclusion or exclusion of a localization sequence.  
During assembly of the holoenzyme, different isoforms can be co-assembled to form a 
heteromultimer.  The number of subunits in the heteromultimer containing a particular localization 
sequence can alter the localization of the entire holoenzyme [163].  Inclusion of alpha-KAP in the 
heteromultimer can result in anchoring of the holoenzyme to the sarcoplasmic reticulum in muscle 
[164].   It has also been shown that CaMKII can decode the frequency, duration, and amplitude of 
Ca2+spikes into distinct amounts of kinase activity [161].  Isoforms and splice variants of CaMKII 
are capable of responding with different sensitivities to the frequency of Ca2+ oscillations [165].   
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C. elegans does not have as many multifunctional CaMKs as mammals do.  It has genes 
coding for CaMKK, CaMKI, and CaMKII (ckk-1, cmk-1, and unc-43 respectively).  However, 
while there are no isoforms of CaMKII coded by separate genes, there are many different forms 
produced from the single gene.  Wormbase.org lists greater than 15 variants encoded by unc-43 
that have been confirmed by cDNAs (Figure 23).  It is possible that some of these variants take on 
roles usually filled by other proteins in mammals.  Most of these are produced by alternative 
splicing.  Notably, several are produced by transcription from internal promoters.   
The various forms of CaMKII may be full-length, N-terminal, or C-terminal. Two of the 
C-terminal forms are produced by transcription from the internal promoter.  The C-terminal forms 
K11E8.1m and K11E8.1o have similarities to a mammalian kinase anchoring protein, αKAP.  Like 
αKAP, they contain a NLS, an association domain, and lack a kinase domain.  In mammals, αKAP 
is capable of assembling in the CaMKII holoenzyme and changing its localization [164].  
K11E8.1m and K11E8.1o could serve to localize the holoenzyme to the nucleus or sarcoplasmic 
reticulum.   
N-terminal forms of CaMKII, such as K11E8.1i, have a kinase and CaM binding domain, 
but lack the association domain.  It is not known if the kinase domains of these forms are 
functional, but if it is, then these forms could act in a manner similar to human monomeric CaMKs.  
Still other splice variants have unique stretches of amino acids not found in all splice variants or 
homologous to any portion of a CaMKII in mammals.  There is little basis on which to predict the 
function of these sequences.   
We obtained a mutant worm strain that has a deletion of a promoter region internal to full-
length CaMKII and required for production of the KAP isoform (allele tm2945).  This strain was 
produced from insertion and imprecise excision of a Mariner transposon, resulting in a 
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Figure 23 
Splice forms of CaMKII.  Shown are several of the splice forms of CaMKII found in C. elegans and listed on 
wormbase.org.  Bars show exons and thin lines show introns. The kinase domain is shown in yellow and the 
association domain is shown in blue.  Note that several of the splice forms lack one or the other.  Splice forms 
containing a possible localization sequence (1m and 1o) are boxed in red and enlarged.  The amino acid sequence 
for K11E8.1m is shown.  Note the putative localization sequence shown in orange. 
1m 
1n 
1o 
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506bp deletion and a 4 bp insertion.  Using the method diagrammed in Figure 24, I constructed a 
strain that has the KAP promoter deletion and expresses LacZ in the muscle.  I verified that the 
constructed strain has the ~500 bp deletion by PCR of genomic DNA with primers flanking the 
deletion site (Figure 25).  This strain has been named the internal promoter deletion (IPD) strain.  
The IPD strain does not degrade protein, has a mild movement defect in the swimming and 
backward crawl assay, and prevents LY-induced degradation (Figure 26).  In Western blots, these 
worms show a reduction in P-CaMKII and P-MEK-2 (Figure 27).  In all respects, the IPD strain 
behaves as a CaMKII rf strain.   This is particularly interesting as the KAP form of CaMKII is not 
catalytically active and contains what may be a localization sequence.  The KAP form could 
assemble into the holoenzyme and then change the localization of the holoenzyme.  Although these 
results are suggestive, it is possible that the internal promoter deletion is altering splicing of full-
length CaMKII, resulting in the rf phenotype.  To test this possibility, PCR of full-length unc-43 
cDNA could be performed. 
 RNAi treatment can potentially be used to knock down individual forms of CaMKII.  The 
Jacobson lab previously had unc-43 and unc-43-3’ RNAi strains.  The unc-43 RNAi is designed 
to knock down all forms of CaMKII.  The unc-43-3’ RNAi is designed to knock down full-length, 
C-terminal, and KAP forms, leaving only N-terminal forms.  I constructed unc-43 cDNA, unc-43-
5’, and KAP RNAi strains (Figure 28), which have been verified by sequencing (Appendix B).  
Unlike the unc-43 RNAi strain, the unc-43 cDNA strain does not produce dsRNA that 
includes introns. The unc-43-5’ RNAi is designed to knock down full-length and N-terminal 
CaMKII, leaving only C-terminal forms. The KAP RNAi is designed to knock down only the KAP 
form of CaMKII.  Exon-specific RNAi sometimes poses a problem in C. elegans due to 
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Mating scheme for generation of tm2945 lacZ strain.  Males containing LacZ on V and GFP on IV were mated 
with tm2945 hermaphrodites (the IPD strain with a mutant unc-43 on IV).  Offspring with dim (1/2) GFP were 
picked to individual plates and allowed to self.  From the clones containing GFP, individuals containing no GFP 
were again picked to individual plates and allowed to self.  These individuals should be homozygous for the mutant 
unc-43.  Several individuals from each of the clones were stained for LacZ in order to identify which clones are 
also homozygous for LacZ. 
 
Figure 24 
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Figure 25 
DNA gel of PCR from single-worms showing successful generation of a tm2945 (IPD), LacZ strain.  Both the 
original tm2945 strain and the tm2945 4-1 strain generated by the cross have a PCR product of 790 bp due to the 
502 bp deletion, in contrast to tm2854 3-2B, with a 244 bp deletion. 
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Figure 26 
The unc-43 IPD strain phenocopies the unc-43 null strain.  a) wt, CaMKII null, and IPD worms were grown to 
adulthood at 20C and stained for LacZ.  b) Adult wt and IPD worms were lightly tapped on the head with a needle 
and the number of strokes of backwards movement that each worm made was counted (n=20).  c) wt and unc-43 
null worms were picked as L4s to 160 µM LY294002 or DMSO plates.  48 hours later they were stained for LacZ. 
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Figure 27 
IPD mutation in unc-43 results in reduced P-CaMKII and P-MEK-2.  Adult wt, UNC-43 null, unc-43 rf, and unc-
43 IPD worms raised to adulthood at 20C and collected for western blot samples.  After blotting, the membrane 
was probed for P-CaMKII and then re-probed for P-MEK and actin. 
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Figure 28 
DNA gel showing colony PCR product of each of the successfully generated RNAi strains.  In all cases, the RNAi 
vector with the appropriate insert is larger than the RNAi vector alone.  The correct sequence of each strain was 
further verified by sequencing. 
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“spreading” in the 5’ direction, but we expect that this will not be a problem with the C-terminal 
and KAP RNAi strains, as there is greater than a 10 kb distance to the catalytic domain.   The 
specificities of these RNAi strains can be tested using RT-PCR.  I have done some preliminary 
work with these RNAi strains, but thus far the results are inconclusive.    These strains remain in 
the lab and can be used by future members to pursue answers to questions revolving around the 
role of splice forms of CaMKII in signaling for muscle protein degradation. 
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3.0  SIGNIFICANCE 
3.1 CAMKII AND MUSCLE PROTEIN DEGRADATION VIA AUTOPHAGY 
3.1.1 CaMKII hyperactivation as a cause of muscle wasting 
While increased expression of CaMKII has been observed in denervated and aging rat 
soleus muscle [166], CaMKII activity has more often been shown to be correlated with muscle 
hypertrophy [113].  CaMKII calcium-independent activity is induced by both acute exercise and 
long-term endurance training in animal models and is correlated with increased muscle protein 
content under these conditions [113]  It is, therefore, thought that the increased expression of 
CaMKII during atrophy in mammalian muscle might actually be a compensatory response, as 
opposed to part of the signal for degradation [113]. 
Despite the correlation between increased CaMKII activation and increased muscle protein 
content with exercise, a causal relationship has not been established.  No inferences should be 
made regarding the role of CaMKII in promoting protein synthesis in animal models of exercise, 
since it has also been shown that during exercise degradation of non-contractile proteins may 
increase while degradation of contractile proteins decreases and that in the recovery period after 
intense exercise degradation of contractile proteins is increased [98].  This is especially true when 
one considers that in rats the different isoforms of CaMKII have been shown to be differentially 
activated and expressed under conditions of atrophy and hypertrophy [167].  It is most likely that 
varying levels of activity of the several isoforms of CaMKII can cause activation of multiple 
downstream pathways.  Some of these pathways may directly or indirectly promote protein 
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degradation, while others may promote protein synthesis.  It will be the combination of signaling 
through multiple pathways during hypertrophy or atrophy that will determine net gain or loss of 
protein in a particular state. 
What my work has done is to establish a clear link between CaMKII activity and protein 
degradation via autophagy in muscle, as well as detail the pathway by which they are linked.  I 
have shown that the activation of autophagy by CaMKII is the result of activation of specific, 
downstream substrates, and not a generalized response to the stress of CaMKII hyperactivation.  
This is especially evident in the fact that the effects of CaMKII hyperactivation on autophagy can 
be compensated for by changes in signaling in distant branches of the network.   
This link between CaMKII activity and autophagy should be further explored in 
mammalian models of hypertrophy and atrophy.  It is possible that activation of CaMKII and 
increased autophagy may play a role in the degradation of soluble proteins for energy metabolism 
during exercise or in exercise-induced muscle remodeling, an adaptive process which includes 
fiber type transformation, mitochondrial biogenesis, angiogenesis, and improved insulin 
sensitivity and metabolic flexibility [168].  Likewise, high intracellular calcium levels present in 
some types of atrophy [43, 114-116] may cause increased CaMKII activity and thereby increased 
autophagy, which may contribute to net loss of muscle protein.  Further studies regarding the role 
of CaMKII in promoting autophagy in muscle would therefore be of interest both to those looking 
to build muscle mass and to those looking to prevent its loss. 
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3.1.2 A novel role for FEM-2 
FEM-2 is a serine/threonine phosphatase type-2C (PP2C).  Although it has been shown to 
dephosphorylate human and worm CaMKII in vitro [144, 145, 169], it is most well-known for its 
role in sex-determination in C. elegans [144].  Unlike other genes involved in C. elegans sex 
determination, fem-2 is well conserved in rats and humans and is expressed outside of the worm 
germ line in both males and females throughout development [145].  This has led to the hypothesis 
that worm FEM-2 has roles outside of sex determination and that these roles may be conserved for 
human FEM-2 [144], [145].  One of these roles has been shown to be promotion of apoptosis in 
mammalian cells, possibly through the inactivation of CaMKII [145]. 
I have shown that FEM-2 reduction-of-function causes an increase in the amount of active, 
P-CaMKII in vivo in C. elegans.  Based on the previous in vitro studies described above, this is 
likely due to FEM-2 functioning to directly dephosphorylate CaMKII.  Therefore, through 
dephosphorylation of CaMKII, FEM-2 negatively regulates autophagy in C. elegans body-wall 
muscle.  This, then, is another example a function of FEM-2 outside of sex-determination that may 
be conserved in humans.  Historically, protein phosphatases have received less attention in 
signaling research than kinases; however, phosphatases have been shown to shape the 
spatiotemporal dynamics of signaling pathways and are now being considered as targets of drug 
development [170].  Further studies could address whether FEM-2 likewise regulates autophagy 
in humans, and, if so, in what tissues, under what conditions, and to what effect.   
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3.1.3 Raf S621 as a CaMKII target 
Human C-Raf has been shown to be activated by phosphorylation of S338 by CaMKII 
[171], providing a possible link between calcium signaling and MAPK signaling.  However, S338 
is not conserved in C. elegans LIN-45 Raf.  In C. elegans, this residue is a glutamic acid, which 
may mimic phosphorylation of S338.  I have proposed Raf S621 as a site that may be directly 
phosphorylated by CaMKII, promoting activation of Raf.  Further work could be done to show 
that C. elegans Raf and CaMKII physically interact in vivo and that CaMKII is capable of 
phosphorylating Raf S621 in vitro.  Raf is a proto-oncogene, and the mechanisms of its activation 
are of interest for cancer biology.  If Raf S621 were shown to be a direct target of CaMKII in C. 
elegans, then future work could look to see if CaMKII targets Raf S621 in humans and what effect 
this has on the activation of Raf, especially since this may mean that CaMKII has multiple Raf 
target sites.  If phosphorylation of this site is necessary for Raf activation (as it appears to be in C. 
elegans) then kinases targeting S621, such as CaMKII, will be required to function at a basal level 
if Raf activation is to be stimulated by other pathways.  If phosphorylation of this site is stimulatory 
but not necessary, then other pathways will be able to activate Raf without S621 phosphorylation, 
although S621 phosphorylation will modulate the extent to which activation occurs. 
3.1.4 Module assembly and signaling specificity 
In this thesis I have described a number of canonical signaling events, such as activation 
passing from:  
A. FGFR→GRB2→RasGEF→Ras  
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B. IGFR→IRS→PI3K→PDK-1→AKT 
C. Raf→MEK→MAPK.   
These can be considered signaling modules, and can be assembled en bloc to form a 
network.  Computationally, a signaling module has been defined as “a subset of the original 
biochemical network, which tends to be self-sufficient and have minimal dependency on the rest 
of the network” [172].  While the modules themselves may not be unique, the combinations of the 
modules to form a network in a particular tissue, developmental stage, or organism, may be unique.  
This allows for a set of inputs to be paired with appropriate, specific outputs, without the need to 
reinvent the mechanisms of signaling between them [173].  The way the modules interact with 
each other, for example through feedback, will determine the behavior of the network. 
The data presented here describe a signaling network comprised of growth factor signaling 
and calcium signaling in C. elegans muscle, which, combined with our earlier work [71, 74, 76, 
77, 99], give a picture of how three signaling modules (FGFR, IGFR, and Ca2+) can interact to 
regulate a downstream process (autophagy) and muscle proteostasis.   
Muscle FGFR is activated by LET-756 FGF, produced constitutively by muscle [174].  
This autocrine signal promotes activation of Raf-MEK-MAPK and muscle protein degradation 
[76].  In worms undergoing oscillatory muscle contraction for sinusoidal movement (i.e. receiving 
input from motor neurons), calcium signaling fluctuates with a period in the range of 1 second, but 
is integrated over time by CaMKII [175].  This produces some level of continual kinase activity 
[165] (note P-CaMKII under basal conditions in wt worms, Figure 12), promoting protein 
degradation.  The presence of both FGFR and CaMKII signals means the default state of the 
network is “on”, and the muscle cells are therefore primed to signal for protein degradation.  It is 
only inhibitory IGFR signaling, acting as the brake, which halts this process.   
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This combination of FGFR, IGFR, and calcium signaling modules to regulate autophagy 
may be unique to C. elegans body-wall muscle, or similar combinations may be found in other 
tissues/organisms.  Regardless, study of this signaling network in C. elegans provides an 
opportunity to dissect how signaling pathways are organized such that the requirements of 
specificity are met with the relatively small number of gene products [173] controlling cell 
behavior.  An understanding of the organization of signaling pathways can be applied to the 
engineering of signaling pathways for industrial and pharmacological purposes [176]. 
3.2 INTEGRATION AND BALANCE 
3.2.1 Raf as a signaling hub 
Graph theory analysis has shown that signaling networks display a “bow-tie” structure, in 
that information from multiple extracellular signals is “funneled” to a few intracellular hubs and 
then dispatched to cause diverse responses [177].  In other words, where multiple modules come 
together, a hub is required.  Signaling hubs, or integrators, are responsible for sensing the various, 
possibly contradictory inputs, and responding with the appropriate output.   
In the network described here, one protein, Raf, is responsible for integrating FGFR, IGFR, 
and calcium signals.  While I have discussed Raf activation in the case of S259A mutation, it must 
be remembered that when both the S621 and S259 sites are available for phosphorylation, 
activation of Raf will be a probabilistic process, as both pS259 and pS621 are acted upon by their 
respective kinases and phosphatases.  LIN-45 Raf, then, integrates FGFR, IGFR, and calcium 
signals through the combinatorial phosphorylation state of its four sites.  Although we have a 
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general idea of the effects of each site, we do not yet know the combinatorial rules that govern Raf 
activation.  Furthermore, neither the phosphorylation rate, nor the dephosphorylation rate at each 
site is likely to be independent of the state of the other sites. 
  For illustration, we can consider the hypothesis that pS259 inhibits activation 
independently of the state of S621.  Our data imply that the class of Raf molecules that proceed to 
activation are probably S259-pS621. In physiological conditions where IGFR signaling and 
calcium signaling are balanced, net phosphorylation of the two sites happens at approximately the 
same rate and the majority of Raf molecules are phosphorylated on both S259 and S621 (pS259-
pS621), preventing Raf activation.  In a high calcium state, such as that modeled with the unc-43 
gf worms, phosphorylation of Raf on S621, in competition with its dephosphorylation, will outpace 
that of S259 phosphorylation, and a subset of Raf molecules will be in state S259-pS621, 
promoting Raf relocation, oligomerization, and activation.  IGFR signaling, then, exerts its 
“braking power”, by phosphorylation of Raf S259.  In a low calcium state, such as that simulated 
by denervation, S259 phosphorylation will outstrip S621 phosphorylation and Raf will remain 
inactive.  Indeed, although denervation promotes muscle protein degradation, this does not require 
autophagy, but instead requires the proteasome [71]. 
Human Raf has four more phosphorylation sites than C. elegans Raf [178, 179], expanding 
the possibilities for regulation.  It should be remembered that even the system I have described 
here for LIN-45 Raf is only a part of the story.  Undoubtedly other signals in body-wall muscle 
additionally converge upon Raf.  The mechanisms by which Raf either integrates or isolates 
incoming signals likely depend on subcellular localization and in the assembly of multi-protein 
signaling complexes [180].  In the network I have described here, for example, the scaffold protein 
KSR-1 has been shown to have a role in transduction of the Raf-MEK-MAPK signal.  Further 
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work could be done to understand the mechanism by which Raf integrates the IGFR, FGFR, and 
CaMKII signals. 
The system that I have described here for quantifying the amount of autophagy in a muscle 
cell can also be further utilized to answer questions about the behavior of the network as a whole.  
For example, we can ask if the network is functioning as a switch or as a rheostat, or if the system 
can be turned off once turned on. 
3.2.2 A downstream integrator, unc-51? 
In this work, I have described signaling from Raf-MEK-MAPK promoting autophagy in 
an UNC-51-dependent manner.  I have not identified what proteins are activated (or inactivated) 
between MAPK and unc-51 to promote autophagy.  Work by other members of the Jacobson Lab 
has shown that RSK-p90 kinase (encoded by C. elegans rskn-1 and/or rskn-2) is likely functioning 
downstream of MAPK to promote autophagy.  Raptor or UNC-51 is possibly downstream of RSK, 
based on the presence of potential RSK target sites.   
Raptor is a scaffold protein that promotes activation of TOR, which inhibits autophagy by 
preventing the association of Atg1 (UNC-51) with Atg13 [61].  Formation of the Atg1-Atg13-Atg-
17 complex is required for autophagy [62].  Raptor scaffolds UNC-51 to TOR and thus regulates 
the TOR-UNC-51 interaction.  For signaling from MAPK to promote autophagy, RSK could either 
inhibit Raptor upstream of TOR, or RSK could be an independent, activating input downstream of 
TOR.  If RSK is an independent input to UNC-51 downstream of TOR, then simultaneous 
reduction-of-function in MAPK should prevent protein degradation caused by knockdown of 
TOR.  This has been shown to be the case.   
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What this then implies is that in order to induce autophagy by inhibition of TOR, wild-type 
levels of MAPK activity are required.  Therefore, UNC-51 may be acting to integrate TOR and 
MAPK signaling.  Further work needs to be done to verify the position of RSK, TOR, and UNC-
51 in the network, but what these data suggest is that MAPK can activate autophagy independent 
of TOR inactivation.  Activation of autophagy in starvation by inactivation of TOR has been well-
characterized, but not as much is known about activation of autophagy in the fed state, when it is 
required for the clearing of damaged proteins and organelles and has been shown to be TOR-
independent [181].  
3.2.3 Maintaining the balance 
In higher eukaryotes, autophagy is required for maintenance of tissue and cell homeostasis, 
as well as for protection from cancer and disease [181].  In muscle, autophagy is required for 
maintenance of muscle mass and prevention of myopathy [50, 58].  I have shown that knockdown 
of unc-43 (CaMKII) by RNAi leads to a decrease in autophagy below that what is seen in null 
RNAi-treated animals.  Shephard et al. [151] have shown that knockdown of unc-43 leads to 
defects in myofibril and mitochondrial maintenance. 
Due to the role of autophagy in the turnover of damaged organelles and proteins, it is 
unsurprising that autophagy is important for healthy aging.  Lifespan extension is seen in C. 
elegans under conditions which promote autophagy, and it is thought that healthspan may be 
increased in higher eukaryotes by preventing age-related decreases in autophagy [182].   
In C. elegans, age-related deterioration of body-wall muscle is correlated with impaired 
movement and is delayed in PI3K (age-1) lifespan-extension mutants [149]. Nuclear localization 
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of DAF-16, a transcription factor sequestered from the nucleus by Akt, is necessary but not 
sufficient for life-span extension in C. elegans [183]. On the other hand, blockage of Akt activity 
is both necessary and sufficient for lifespan extension, meaning that Akt likely inhibits other 
proteins that are involved in processes promoting lifespan extension [183]. Since CaMKII counters 
Akt activity at Raf, it would be interesting to see if unc-43 RNAi treatment is sufficient to shorten 
lifespan and if CaMKII gf mutation is sufficient to extend lifespan.  If lifespan is affected by 
variations in CaMKII activity, then further studies regarding lifespan and healthspan could be done 
with this system.  
3.2.4 Mobilizing a resource 
The muscle cell is poised to degrade its contents; in light of its role as a protein reservoir, 
this may aid in the rapid mobilization of amino acids when they are needed.  Unfortunately, 
excessive protein breakdown can lead to muscle wasting, which is a difficult condition to reverse 
[48].  It is thought that the signaling mechanisms of disease lead to a change in the set-point of 
metabolism, such that protein degradation is enhanced and protein synthesis is inhibited [48].  Net 
protein degradation seen in catabolic conditions might then be treated by increasing protein 
synthesis and/or decreasing protein breakdown.  How this is done will depend on many factors, 
including the age of the patient, who already may have altered metabolism. 
For example, note that the degradation seen in CaMKII gain-of-function animals is 
progressive—young CaMKII gain-of-function worms do not show net loss of muscle protein, 
while mature and aging CaMKII gain-of-functions worms do.  With the growth that is occurring 
during development, protein synthesis exceeds protein degradation and there is no net loss of 
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protein.  It is only in the mature and aging animal, that the protein degradation phenotype becomes 
evident.   
In muscle wasting, re-establishment of the balance between protein synthesis and 
degradation should be the goal, especially since therapies revolving around simply increasing 
protein intake by the patient have been shown to lack efficacy [48].  Despite this, therapies 
designed to target the signaling pathways leading to increased protein degradation have yet to be 
implemented, largely due to an imperfect understanding of the relevant networks. I have shown 
that co-modulation of seemingly disparate pathways can influence the downstream development 
of a pathological state.  This implies that in diseases such as muscle wasting, where aberrant 
signaling is leading to disease, therapeutic targets may be found in pathways less obviously 
associated with the disease.  Having targets in alternate pathways can be beneficial for the design 
of therapeutics if the main pathway is difficult to target.  Pathways that may be difficult to target 
are those through which signaling would need to be increased to produce a desired effect because 
it is easier to design an inhibitor of a protein than to design a method of stimulating the activity of 
a protein.  Additionally, targeting of pathways with many downstream functions can lead to 
unintentional effects. Detailed network maps, which can be tedious to generate, provide a resource 
that can be mined for therapeutic targets as well as reveal possible off-target effects of inhibiting 
a particular protein or pathway.  This means that production of these network maps is potentially 
useful for the development of therapeutics based on modulation of signaling networks and 
production of such maps is a valid research goal. 
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4.0  MATERIALS AND METHODS 
4.1 MEDIA AND REAGENTS 
TB 
10 g Tryptone 
5 g NaCl 
1.5 mL 1M NaOH 
1000 mL ddH2O 
The above were mixed and sterilized by autoclaving. 
 
NGM plates 
2.5 g Bacto-peptone 
 3 g NaCl 
 17 g Bacto-agar  
 975 mL ddH2O 
 The above was mixed and sterilized by autoclaving.  After removal from the autoclave, the 
following was added: 1 ml 0.5% cholesterol in 95% ethanol 
 After the mixture had cooled enough that one could hold ones hands to the flask 
comfortably but before it solidified, the following were added:  
2 ml sterile 0.5M CaCl2, 1 ml sterile MgSO4, 25 ml sterile 1M PO4 buffer, pH 6. 
 After addition of these final ingredients, the media was poured into Petri dishes of the 
appropriate size.  For general use, about 25 ml of the media was poured into 100 mm X 15 mm 
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Petri dishes.  For mating and clonal selection, about 12.5 ml was added to 60 mm X 15 mm Petri 
dishes.  For drug treatment, exactly 5 ml was added to 60 mm X 15 mm Petri dishes by sterile 
glass pipette (herein referred to as “drug plates”). 
   
BU 
 7.01 g Na2HPO4 
 4.0 g NaCl 
 3.0 g KH2PO4 
 1 L ddH2O 
 The above were mixed and sterilized by autoclaving. 
 
LacZ Stain 
 Oxidation Buffer 
32 mM NaH2PO4 
 168 mM Na2HPO4 
 1 M MgCl2 
 5 mM potassium ferrocyanide 
 5 mM potassium ferriccyanide 
 5-bromo, 4-chloro-indolyl-β-D-galactosidase (X-gal, 30 mg/mL in N,N-diMe-formamide) 
and oxidation buffer (in 200 µL aliquots) were stored at -20C.  For use, one aliquot of oxidation 
buffer was thawed and 4 µL of X-gal was added to a final concentration of 0.006 mg/mL.  
Additionally, the thawed mixture should be warmed in the palm of the hand until no precipitate is 
visible immediately prior to use. 
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LB + antibiotic plates 
 10 g peptone 
 5 g yeast extract 
 5 g NaCl 
 17 g agar 
 1 L ddH2O 
 The above were mixed and sterilized by autoclaving.  After the media had cooled 
sufficiently, 1 µL filter-sterilized, 25 mg/mL Carbenicillin, 10 mg/ml Kanamycin, or 0.1 mg/mL 
Tetracycline, was added per mL of TB and the plates were poured. 
 
TB + carbenicillin broth 
 10 g Tryptone 
 5 g NaCl 
 1.5 mL 1M NaOH 
 1 L ddH2O  
 The above were mixed and sterilized by autoclaving.  Prior to use, 1 µL filter-sterilized, 25 
mg/mL Carbenicillin was added per mL of TB. 
 
RNAi lite plates 
 1.5 g NaCl 
 4 g tryptone 
 20 g agar 
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 980 mL ddH2O 
 The above were mixed and sterilized by autoclaving.  When the media had partially cooled, 
the following were added and the plates were poured:  
25 mL 1M phosphate buffer (108.3 g anhydrous KH2PO4 and 35.6 g anhydrous K2HPO4 
in 1 L ddH2O and autoclaved.) 
 2 mL 0.5 M CaCl2 
 1 mL 5mg/mL cholesterol in ethanol 
 10 mL lactose (20% solution, autoclaved) 
 1 mL 0.5M IPTG in ddH2O 
 1 mL 25 mg/mL carbenicillin 
 
4X SDS  sample buffer 
 1.6 mL 0.5 M, pH 6.8 Tris (final 0.16M) 
 1 mL Glycerol (final 20%) 
 0.4 mL ß-mercaptoethanol (final 0.1%) 
 2 mL 20% SDS (final 8%) 
 40 µL 1% bromphenol blue (0.01%) 
  
Running Buffer 
 12.1 g Tris base (final 25mM) 
 57.6 g Glycine (final 192mM) 
 4 g SDS (final 0.1%) 
 4L ddH2O 
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 The above were mixed and titrated to a pH of 8.6 with NaOH 
 
Electroblot Buffer 
 600 mL methanol (final 20%) 
 9.11 g Tris base (final 25mM) 
 43.24g Glycine (192mM) 
 2.4 L ddH2O 
 The above were mixed.  The pH should be approximately 8.3.  This solution should not be 
titrated. 
 
Tris-buffered saline (TBS) 
 1.21 g Tris base (final 10 mM) 
 8.766 g NaCl (final 150mM) 
 1 L ddH2O 
 The above were mixed and titrated to a pH of 8 with HCl.  If the protocol called for TBS 
with Tween, then Tween-20 was added to a final concentration of 0.2%. 
4.2 BACTERIAL STRAINS 
The E. coli strain OP50, a uracil auxotroph, was obtained from the Caenorhabditis 
Genetics center (CGC).  For feeding to C. elegans, OP50 was grown overnight in approximately  
250 ml of TB and then 500 µL was plated per NGM plate.  When not used immediately, OP50 
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culture was stored at 4°C for future use.  OP50, a uracil auxotroph, is used due to its limited growth 
on NGM, preventing the development of an over-thick lawn.  Most RNAi bacteria were obtained 
from the Ahringer Collection (Cambridge GeneService), unless they were constructed in-house as 
described in section 4.14. 
4.3 NEMATODE STRAINS 
The nematode strains used in this work are listed in Appendix A.  All strains were 
maintained on NGM plates seeded with OP50 at 20°C, unless the nematode strain is indicated as 
being temperature sensitive, in which case the strain was maintained at 16°C.  For strain 
maintenance, after the worms had consumed the E. coli on their old plate, a chunk of that plate 
was transferred to a fresh, seeded plate.  In some cases, strains were maintained by picking 
individuals displaying the phenotype of the strain from a spent plate to a fresh plate. 
In order to construct strains with more than one unlinked mutation or integrated transgene, 
standard genetic crosses were done.  The scheme shown in Figure 24 is an example of a standard 
cross.  In this case, as in most others, some integrated transgene (e.g., pharyngeal GFP driven by 
the myo-2 promoter) or mutation with obvious phenotype (e.g., daf mutation) was used as a 
repulsion marker.  In all cases, males for use in crosses were obtained by choosing or creating 
strains for mating with him-8 or him-1 mutation.  Worms with him mutation have a high incidence 
of males in the population. 
EMS mutagenesis was conducted to obtain suppressors of the unc-43 n498 gf allele.  After 
mutagenesis, individuals showing increased mobility were selected from the F2.  One of these 
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individuals contained what has become the n498j037 null allele.  Double-stranded sequencing of 
the unc-43 gene from these individuals revealed that this allele has the n498 gf mutation as well 
as a second mutation resulting in a D236N substitution in the active site of the enzyme (see 
Appendix C).  Western blots have showed that homozygous n498j037 individuals have no pT286-
CaMKII (Figure 29), leading us to conclude that this is likely null for CaMKII protein activity. 
4.4 HISTOCHEMICAL STAINING 
β-galactosidase activity  
10-20 worms were picked into a 20 µL drop of BU placed on a frosted, glass slide.  After 
the worms were picked into the BU, the slides were placed in a vacuum desiccator and allowed to 
dry at least until no liquid BU was visible and usually for about ninety minutes.  Although usually 
by 45 minutes no liquid BU is visible, longer drying times consistently produce better stains.  After 
drying, the slides were fixed at -20C in acetone in a Coplin jar for 3.5 minutes.  Upon removal 
from the acetone, the slides were placed on aluminum plates at room temperature and allowed to 
dry for 12 minutes.  Shorter drying times do not allow all the acetone to evaporate and result in 
poorly stained worms.  Extended drying times allow the fixed worms to absorb moisture from the 
air and also results in poor staining.  Drying times post-fixation in acetone may need to be adjusted 
based on room humidity.  After drying, 20 µL of X-gal stain was added to each sample, as 
described [74] for 1.5-3h at room temperature.  Every experiment included control animals, such 
that the length of staining was appropriate and did not result in over- or under-stained animals.  
During staining, slides are kept in a humidor composed of a large petri 
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CaMKII null mutants lack P-CaMKII.  a) wt and unc-43 null worms were grown to adulthood at 20C and harvested 
for western blotting for pT286 CaMKII. 30 worms/lane. 
Figure 29 
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dish containing a wet paper towel and sealed with parafilm to prevent drying of the slides.  The 
worms stain blue where β-galactosidase is present (Figure 30).  A benefit of this method, as 
opposed to a fluorometric assay of β-galactosidase activity, is that it is possible to see in which 
muscles and in what individuals β-galactosidase activity is present, instead of it being averaged.   
 
Phalloidin Staining 
 Slides were prepared as for β-galactosidase staining, except they were fixed in acetone at -
20C for 5 minutes.  After fixation, slides were allowed to dry as above and then 20 µL of Phalloidin 
stain (2 units RITC-labeled Phalloidin from Molecular Probes, Inc. in 5% methanol) was added to 
each sample.  After addition of stain, slides were sealed in a humidor and incubated overnight in 
the dark at room temperature before imaging. 
4.5 BRIGHT-FIELD AND FLUORESCENCE MICROSCOPY AND IMAGING 
For LacZ stains, after staining was completed, each slide was covered with a cover slip and 
observed with bright-field microscopy.   Digital images were taken at approximately the same 
exposure for all images.  Later, images were processed with Adobe Photoshop or Corel PHOTO-
PAINT X6.  Processing of the images involved equalization of color and illumination quality, as 
well as construction of composite images.  When color corrections were made, they were applied 
equally to all areas of a composite.  
 GFP-expressing or phalloidin-stained worms were illuminated with UV light and observed 
with the appropriate filter.  For GFP images, live worms were picked into 20 µL of BU 
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Figure 30 
Diagram of the mechanism by which LacZ staining produces blue color. 
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and covered with a cover slip.  When the worms’ movement slowed enough for photography, 
images were collected at the same exposure. 
4.6 RNAI TREATMENT 
E. coli bacteria expressing gene-specific dsRNA were maintained on LB + carb plates.  For 
use, one colony from the stock plate was picked into 5 mL of TB + carb broth and grown overnight 
by shaking in a 37C water bath.  In all cases, null RNAi, consisting of the RNAi plasmid with no 
gene insert, was prepared and used concurrently with treatment RNAis as a negative control.  After 
overnight growth, 250 µL of each culture was added to 750 µL of fresh LB + carb broth.  To this, 
10 µL of 0.5M IPTG was added and the tube was shaken in the 37C water bath for 4-5 hours.  
While the cultures grew, RNAi lite plates were placed on the bench to warm to room temperature.  
After the 4-5 hour incubation, 250 µL of RNAi culture was spread on the RNAi lite plate.  Seeded 
plates were then incubated at 37C overnight.  The next day, 5-10 L4 worms of the nematode strain 
of interest as well as the control strain were picked to the treatment and control RNAi plates.  The 
plates were then stored at the temperature appropriate for the strain of interest.  The L4s initially 
plated were allowed to grow to adulthood and lay the F1 on the RNAi plates.  When the F1 reached 
L4 or adulthood (as appropriate for the experiment), they were harvested for further use.  If the 
worms were being used for LacZ stains, they were  picked to OP50 and allowed to crawl around 
for 2-24 hours to excrete the RNAi bacteria, which also contain ß-galactosidase. 
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4.7 SYNCHRONIZING WORM GROWTH 
Plates of worms were grown until there was a large population of L1s and the E. coli food 
source had decreased.  3 mL of BU was then added to the surface of the plate, was swirled around, 
and then pipetted back up from the surface of the plate.  The BU containing the worms was then 
added to a 15 mL centrifuge tube and allowed to sit for 2 minutes.  Larger worms sink faster, and 
after 2 minutes the top 0.5 mL of BU, containing all L1s, was pipetted off and plated. 
4.8 MOVEMENT ASSAYS 
Well-fed, young-adult worms were picked into 20 µL of BU on a frosted, glass slide and 
observed under the dissecting scope.  With a stop watch, the number of seconds it took for each 
worm to wag its head back and forth ten times was counted.  This was converted into 
strokes/minute.  For each worm observed, ten measurements were collected. 
4.9 TEMPERATURE SHIFT 
Prior to a temperature shift experiment, all worm strains, including controls, were kept at 
16C.  When the plates contained worms of the appropriate age, the worms were either settle 
synchronized, as described above, and allowed to grow to L4/young adult before use, or were 
hand-picked as L4s by inspection.  For experiments requiring larger numbers of animals, the first 
method was used, while for experiments requiring less than about one hundred animals the second 
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method was used, since it allows for tighter control of age.  Control animals were kept at 16C, 
while the experimental group was shifted to 25C.  The experimental group remained at 25C for 
24, 48, or 72 hours, as indicated, at which point they were stained for LacZ, used for movement 
assays, or collected for Western blot samples. 
For heat shock experiments, worms were placed at 37C for 30 minutes before being 
transferred to 25C for 48 hours.  Afterwards, samples were treated as described above. 
4.10 IMMUNOBLOTTING 
For Western blot samples, thirty worms were picked into 20 µL sterile ddH2O. Immediately 
following picking, samples were frozen in liquid nitrogen and stored at -20C until use.  4X SDS 
buffer was warmed in the palm of the hand until fully liquid, then 8 µL was added to the frozen 
samples.  A hot water bath was prepared by bringing a tray of water to boiling and then allowing 
to cool for two minutes.  After cooling, the samples were placed in the hot water bath for two 
minutes.  After the bath, the samples were agitated on a vortex mixer for five minutes and then 
centrifuged for 1 minute.  Samples were then loaded into 12% or 4-20% gel cassettes from Lonza 
and run at approximately 120 volts for 1.5 hours.   
To prep the Immobilon-P PVDF membrane (Millipore) for blotting, it was soaked for 3 
minutes in methanol, 2 minutes in ddH2O, and then left sit in electroblot buffer.  The gels were 
loaded with the membrane into the electroblotter and allowed to sit for 15 minutes before blotting.  
They were electroblotted for 45 minutes at 12V, at which point the membrane was removed and 
blocked for 1 hour in a concentration of bovine serum albumin (BSA) or non-fat dry milk (NFDM) 
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in TBS + tween at a concentration optimized for the particular antibody.  After blocking, the 
membrane was washed four times for five minutes each in TBS.  The membrane was then 
incubated with the primary antibody in an optimized percentage of   BSA or NFDM in  TBS + 
tween overnight at 4°C with shaking.  Primary antibodies used are listed below.  In the morning, 
the membrane was washed with TBS four times for five minutes each and then incubated with the 
secondary antibody in the appropriate concentration of BSA or NFDM in TBST.  The secondary 
antibodies were obtained from Jackson Immunoresearch and were peroxidase-conjugated, affinity-
purified, donkey anti-mouse or anti-rabbit.  After the blots were again rinsed in TBS four times for 
five minutes each, they were incubated with TMB peroxidase substrate (KPL) for detection.  After 
detection they were rinsed in ddH2O and allowed to dry.  After drying, they were scanned and, 
where indicated, were analyzed with ImageJ software.   
In all cases, blots were stripped by incubation in Restore PLUS stripping buffer (Thermo 
Scientific) for 7 minutes and then re-blocked and re-probed for actin as a loading control.  Where 
blots were quantified, the amount of signal for each sample was calculated by dividing the amount 
of signal for the first primary antibody by the amount of actin signal.  In some cases, blots were 
stripped and re-probed multiple times to detect various proteins of interest. 
 
Primary antibodies 
anti-pT286-CaMKII (Cell Signaling Technologies, no. 3361) 
anti-QETVD CaMKII (Signosis, Ab-286) 
anti-pS621 Raf (Abcam ab58542) 
anti-P-MEK ( Cell Signaling Technologies, no. 9121) 
anti-P-MAPK (Cell Signaling, #9101) 
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anti-actin (Developmental Studies Hybridoma Bank, JLA-20) 
The following primary antibodies were purchased from Cell Signaling Technologies:  anti-
pTpY-ERK (no. 9101), anti-ERK (no. 9102), anti-MEK (no. 9122). Anti -pT598pS601-BRaf (no. 
sc-28006) was from Santa Cruz Biotechnologies.  
4.11 STATISTICAL ANALYSIS 
Unless otherwise noted, all error bars represent standard errors of the mean.  Statistical 
significances in differences between treatments were calculated using the Student’s T-test, unless 
otherwise noted.  Other methods of determining statistical significance used in this work are the 
chi-square test for independence and the Wilcox Rank Sum Test.  In the case of the Chi square 
test, data were binned for each population prior to application of the test.  p values less than 0.05 
were considered significant. 
4.12 CONFOCAL MICROSCOPY 
For confocal microscopy, live animals were picked into 20 µL of BU on a frosted, glass 
slide and covered with a cover slip suspended by two dots of ink from a hydrophobic pen at 
opposite corners.  After movement of live worms had slowed enough for photography, an Olympus 
FV1000 confocal microscope was used to observe autophagic vesicles in the muscle “belly”. The 
depth of focus of the microscope exceeds the thickness of the muscle belly, so images at multiple 
focal planes were not taken.  The focal plane containing the belly region of the muscle cells was 
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Figure 31 
Characteristic LGG-1::GFP fluorescence in three different planes of C. elegans muscle cells as viewed by 
confocal microscopy: a) myofilament lattice, b) muscle belly, c) under the muscle cells.  When collecting images 
for quantification of autophagic vesicles, the muscle belly plane was located relative to the myofilament lattice.  
It was additionally verified that other fluorescent structures did not underlie the muscle belly, to avoid 
complicating the analysis. 
A B C 
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located relative to the rows of GFP::LGG-1 fluorescence associated with the sarcoplasmic 
reticulum, which is associated with the microfilament lattice (Figure 31).  Autophagic vesicles 
were counted manually from the confocal images, and normalized to the area examined using 
ImageJ software.  
4.13 DRUG TREATMENT 
N6,N6-dimethyladenosine (DMA) 
 To prepare DMA plates, 50 µL of 50mM DMA in DMSO (Toronto Research Chemicals) 
was added to 5 mL NGM drug plates (prepared as described in section 4.1) to a final concentration 
of 0.5mM.  The drug was sprinkled over the surface of the plate, and then the plate was rocked at 
room temperature for 24 hours.  Approximately thirty L4 worms (experimental or control) were 
added to each plate.  Worms were also added to control plates, which contained 1% v/v DMSO 
and were prepared in the same manner as the DMA plates.  Plates were then maintained at 20C.  
After 48 hours, an additional dose of 50 µL of 50mM DMA was added to each plate.  72 hours 
later pictures of autophagic vesicles were obtained by the method described in section 4.12 of 
young-adult F1 worms (24 hours post-L4). 
 
Cycloheximide 
 To prepare cycloheximide plates, 100 µL of 20 mg/mL cycloheximide (in H2O) was added 
to 5 mL NGM drug plates, prepared as described in section 4.1.  The final concentration of 
cycloheximide was 400 µg/mL.  Plates were incubated on a rocker overnight at room temperature 
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and then were sealed and refrigerated for no more than one week before use.  L4 worms were 
picked to cycloheximide plates and were incubated for 48 hours at the temperatures needed for the 
experiment.  DMSO plates at 1% v/v were prepared and maintained in the same fashion.  The 
survival rate of worms on cycloheximide at the non-permissive temperature was approximately 
10% after 48 hours.  
 
LY294002 
To prepare LY294002 (BioMol, Enzo Life Sciences) plates, 50 µL of 16mM LY294002 in 
DMSO was plated onto 5 mL drug plates to a final concentration of 160uM.  Plates were incubated 
at room temperature for 24 hours.  Young adult or L4 worms were added to the plates and collected 
48 hours later for Western blotting and LacZ staining.  Control plates contained DMSO alone at 
1% v/v.  
4.14 RNAI STRAIN CONSTRUCTION 
RNAi strains are constructed by transforming E. coli containing T7 polymerase under 
control of the lac operon with a plasmid (L44440, Fire collection) containing the gene of interest 
flanked 5’ and 3’ by the T7 promoter.  Upon induction with IPTG, T7 polymerase is produced and 
transcribes the gene of interest, resulting in dsRNA. 
To construct the plasmid containing the gene of interest, the gene of interest was amplified 
by PCR from the source and using the primers listed below (Go Taq polymerase, Promega). The 
L4440 plasmid, which we use for null RNAi treatments and which contains a multiple cloning 
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region and an ampicillin resistance gene, was isolated from E. coli maintained in the lab (QIAprep 
Spin Miniprep Kit, Qiagen).  Both the PCR product and the L4440 plasmid were digested with the 
appropriate restriction enzymes, as listed below (NEB).  If the plasmid was treated with Calf 
Intestinal Alkaline Phosphatase (CIP, NEB), it was subsequently gel-purified (Wizard SV gel and 
PCR clean-up system).  The digested PCR product was also gel-purified.  After purification, the 
PCR product and digested plasmid were ligated (T4 ligase, NEB).  After ligation, the resultant 
plasmids were digested with a restriction enzyme (NEB) whose site in the multiple cloning region 
of L4440 was no longer present in the recombinant plasmid.  This served to counter-select against 
plasmids that did not contain the gene of interest. Competent cells (OneShot Omnimax 2-T1R, 
Invitrogen) were transformed with the recombinant plasmid.  Colony PCR (Go Taq Polymerase, 
Promega), using the following primers external to the insert, was performed to identify colonies 
containing the recombinant plasmid. 
Primers:  R 5’GGC CTC TTC GCT ATT ACG C 
  L 5’GGA GAC CGG CAG ATC TGA TA 
After colonies containing the recombinant plasmid were identified, plasmid DNA was 
isolated and sent for sequencing (Genewiz).  Plasmids containing the gene of interest with no 
sequencing variations were selected for further use and were transformed into the bacterial strain 
used for RNAi, HT115 (DE3), which contains the gene for T7 polymerase under control of the lac 
operon, and lacks double-stranded RNAse III.  RNAi plasmids in HT115 are maintained on LB + 
carb plates to select for the RNAi plasmid, but resultant strains were also streaked on Tet to verify 
the Tet-resistance of the HT115 strain.  Colonies able to grow on both Carb and Tet were further 
verified to contain the RNAi plasmid by colony PCR. 
unc-43-5’ 
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PCR template: pKU24, plasmid containing unc-43 cDNA  
Primers:  R 5’CGC GCG TCG ACT CAA AA CCA GAT AA 
  L 5’TAT ATA CTG CAG GGT GCC TTC TCA 
Restriction enzymes: SalI, Pst1, counter-selection - HindIII 
NLS RNAi 
PCR template: C. elegans genomic DNA 
Primers: R 5’TAT ATA GCG GCC GCA CAT CAT CGT CAG TAA TA 
  L 5’CGC GCG CTG CAG ACT TCT AAC TTC TCA GGT T 
Restriction Enzymes: NotI, PstI, counter-selection – NheI 
 
unc-43 cDNA RNAi 
No PCR was needed in the construction of this strain, as a plasmid, pKU24, already 
containing the unc-43 cDNA, was present in the lab.  The portion of pKU24 to be inserted into the 
RNAi plasmid was removed by digestion of pKU24 with KpnI and NheI.  After ligation of the 
fragment with L4440, plasmids were counter-selected with PstI.  
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APPENDIX A 
STRAINS OF C. ELEGANS USED 
 
Description Strain code Genotype 
wt PD55 tra-3(e1107) IV; sup-7; unc-54::lacZ (ccIs55) V 
unc-43 (CaMKII) gf PJ1182 unc-43(n498) IV; ccIs55 unc-54::lacZ V; Punc-54::daf-
2+, Pgoa-1::GFP, rol-6 extrachromosomal (njex38) 
unc-43 promoter::gfp BC11417 dpy-5(e907); sEx 11417 [rCes K11E8.1d::GFP + 
pCeh361) unc-43::GFP 
fem-2ts rf PJ1703 fem-2(b245ts) III; ccIs55 (unc-54::lacZ) V 
unc-43 gf; mpk-1 rf PJ1720 mpk-1(n2521) III; him-8 (e1489), unc-43(n498) IV; unc-
54::lacZ (ccIs55) V; Punc-54::daf-2+, Pgoa-1::GFP, rol-
6 extrachromosomal (njex38) 
CaMKII activity null PJ1304 unc-43(n498) IV; ccIs55 unc-54::lacZ V; ??? (j037); 
Punc-54::daf-2+, Pgoa-1:GFP, rol-6 extrachromosomal 
(njex38) 
 
unc-43 rf PJ1088 unc-43(e408) IV; ccIs55a(unc-54::lacZ) V 
CaMKII IPD PJ1295 unc-43(tm2945) IV; unc-54::lacZ (ccIs55) V 
 
CaMKII protein null PJ1251 unc-43(n1186 n498) IV; unc-54::lacZ(ccIs55) V 
Constitutively active 
Dros. MEK with 
heat shock-inducible 
MAPK 
 
PJ1115 gaIs37  (pEF1α::Dmek hs::mpk-1) IV; ccIs55 (unc-
54::lacZ) V 
 
Hyper MAPK; unc-
51 rf 
PJ1236 gaIs37(EF1a::Dmek hs::mpk-1) IV; unc-51(e369) unc-
54::lacZ(ccIs55) V 
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unc-43 gf; unc-51 rf PJ1726 unc-43(n498) IV; unc-51(e369) unc-54::lacZ(ccIs55) V 
unc-43 gf; lgg-1::gfp PJ749 unc-43(n498gf) IV; adIs2122 [lgg-1::GFP + pRF4(rol-
6(su1006)] ? 
lgg-1::gfp DA2123 adIs2122 [gfp::lgg-1 + pRF4(rol-6(su1006)] ? 
 
unc-43 rf; daf-2ts rf PJ1729 daf-2(m41ts) III; unc-43 (e408) IV; unc-54::lacZ (ccIs55) 
V 
 
daf-2ts rf 
 
 
 
PJ1123 daf-2(m41ts) III; ccIs55(unc-54::lacZ) V 
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APPENDIX B 
RNAi SEQUENCE DATA 
 
unc-43 cDNA RNAi vs. unc-43 spliced 
 
Comparison of: (A) ./wwwtmp/.30097.1.seq cDNA unc-43-L 1190 bp                              
- 1190 nt (B) ./wwwtmp/.30097.2.seq unc-43e spliced 2505 bp                            
- 2505 nt  using matrix file: DNA (5/-4), gap-open/ext: -14/-4 E(limit)   0.05    
94.1% identity in 1140 nt overlap (66-1189:225-1361); score: 5080 E(10000): 
  
          70        80        90       100       110       120       
cDNA   ATGATGAACGCAAGCACCAAGTTTAGTGACAATTACGATGTGAAGGAGGAACTTGGAAAA         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 ATGATGAACGCAAGCACCAAGTTTAGTGACAATTACGATGTGAAGGAGGAACTTGGAAAA            
          230       240       250       260       270       280  
               
         130       140       150       160       170       180       
cDNA   GGTGCCTTCTCAGTTGTTCGTCGTTGTGTTCATAAAACCACGGGCCTCGAGTTTGCTGCC         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 GGTGCCTTCTCAGTTGTTCGTCGTTGTGTTCATAAAACCACGGGCCTCGAGTTTGCTGCC 
          290       300       310       320       330       340  
     
         190       200       210       220       230       240 
cDNA   AAAATCATCAACACAAAGAAGCTATCCGCTCGTGACTTTCAGAAACTTGAGAGGGAAGCC         
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
unc-43 AAAATCATCAACACAAAGAAGCTATCCGCTCGTGACTTTCAGAAACTTGAGAGGGAAGCC 
          350       360       370       380       390       400      
 
         250       260       270       280       290       300       
cDNA   AGAATTTGCAGAAAACTCCAGCATCCAAATATTGTTAGACTACACGACAGTATTCAAGAG         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 AGAATTTGCAGAAAACTCCAGCATCCAAATATTGTTAGACTACACGACAGTATTCAAGAG 
          410       420       430       440       450       460       
 
         310       320       330       340       350       360       
cDNA   GAATCATTCCATTATCTGGTTTTTGATCTCGTTACCGGAGGAGAACTGTTTGAGGACATT         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 GAATCATTCCATTATCTGGTTTTTGATCTCGTTACCGGAGGAGAACTGTTTGAGGACATT     
          470       480       490       500       510       520 
        
         370       380       390       400       410       420       
cDNA   GTTGCTCGCGAGTTTTATTCAGAAGCGGATGCAAGTCATTGCATTCAACAAATTCTCGAA         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 GTTGCTCGCGAGTTTTATTCAGAAGCGGATGCAAGTCATTGCATTCAACAAATTCTCGAA    
          530       540       550       560       570       580                
 
         430       440       450       460       470       480       
cDNA   TCGATTGCTTATTGCCACTCTAACGGTATTGTTCACAGAGACTTGAAGCCAGAAAACTTG         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 TCGATTGCTTATTGCCACTCTAACGGTATTGTTCACAGAGACTTGAAGCCAGAAAACTTG 
          590       600       610       620       630       640                
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         490       500       510       520       530       540       
cDNA   CTTCTCGCATCTAAAGCGAAGGGAGCTGCTGTAAAGCTTGCCGATTTTGGTCTTGCAATC         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 CTTCTCGCATCTAAAGCGAAGGGAGCTGCTGTAAAGCTTGCCGATTTTGGTCTTGCAATC 
          650       660       670       680       690       700                
 
         550       560       570       580       590       600       
cDNA   GAAGTGAACGATAGTGAAGCATGGCACGGATTTGCTGGAACTCCAGGATACTTGTCGCCA         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 GAAGTGAACGATAGTGAAGCATGGCACGGATTTGCTGGAACTCCAGGATACTTGTCGCCA            
          710       720       730       740       750       760                
 
         610       620       630       640       650       660       
cDNA   GAAGTTCTCAAGAAGGATCCATACTCAAAGCCAGTTGATATCTGGGCTTGTGGTGTCATT         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 GAAGTTCTCAAGAAGGATCCATACTCAAAGCCAGTTGATATCTGGGCTTGTGGTGTCATT            
          770       780       790       800       810       820      
           
         670       680       690       700       710       720       
cDNA   CTGTACATCCTTCTTGTTGGATACCCACCATTCTGGGATGAGGACCAACACCGTTTATAC         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 CTGTACATCCTTCTTGTTGGATACCCACCATTCTGGGATGAGGACCAACACCGTTTATAC 
          830       840       850       860       870       880                
 
         730       740       750       760       770       780       
cDNA   GCACAAATCAAGGCTGGAGCCTATGATTACCCGAGCCCCGAATGGGATACGGTGACCCCG         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 GCACAAATCAAGGCTGGAGCCTATGATTACCCGAGCCCCGAATGGGATACGGTGACCCCG            
          890       900       910       920       930       940                
 
         790       800       810       820       830       840       
cDNA   GAGGCAAAAAGCCTCATCGACAGCATGCTGACGGTGAACCCAAAGAAGCGTATCACCGCT              
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 GAGGCAAAAAGCCTCATCGACAGCATGCTGACGGTGAACCCAAAGAAGCGTATCACCGCT            
          950       960       970       980       990      1000                
 
         850       860       870       880       890       900       
cDNA   GATCAGGCCTTGAAAGTCCCATGGATTTGCAATCGCGAACGCGTTGCATCAGCTATCCAC             
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 GATCAGGCCTTGAAAGTCCCATGGATTTGCAATCGCGAACGCGTTGCATCAGCTATCCAC           
         1010      1020      1030      1040      1050      1060                
 
         910       920       930       940       950       960       
cDNA   AGACAGGATACTGTTGACTGCTTGAAGAAATTCAATGCNANGGCGGAAGTTGAAGGNGGC            
       :::::::::::::::::::::::::::::::::::::: : ::::::::::::::: :::  
unc-43 AGACAGGATACTGTTGACTGCTTGAAGAAATTCAATGCAA-GGCGGAAGTTGAAGGCGGC 
        1070      1080      1090      1100       1110      1120               
 
         970       980       990      1000      1010      1020       
cDNA   AATATCGACTGTCAAAATGGTGACACGAATGTCGGNAGTTCTTCNAACTTCCGACTCCCA         
       ::::::: ::::::::::::::::::::::::::: :::::::: ::::::::::::: :  
unc-43 AATATCGGCTGTCAAAATGGTGACACGAATGTCGGGAGTTCTTCGAACTTCCGACTCC-A            
         1130      1140      1150      1160      1170      1180   
          
 
 
 
       1030      1040      1050      1060      1070       1080      
cDNA   CTGGNTCAGNTCGCATCGAATGGATCAACGACGCACGATGCGTCNNNGGNNN-AGGAN-A         
       :::: :::: ::::::::::::::::::::::::::::::::::   ::    ::::  :  
unc-43 CTGGATCAG-TCGCATCGAATGGATCAACGACGCACGATGCGTCACAGGTGGCAGGAACA             
        1190       1200      1210      1220      1230      1240           
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NLS RNAi vs. unc-43 
 
Comparison of: (A) ./wwwtmp/.12748.1.seq RNAi NLS-L 792 bp                                  
- 792 nt (B) ./wwwtmp/.12748.2.seq unc-43m genomic 6826 bp                            
- 6826 nt  using matrix file: DNA (5/-4), gap-open/ext: -14/-4 E(limit)   0.05    
99.6% identity in 242 nt overlap (23-264:220-461); score: 1201 E(10000): 6.3e-91 
 
             30        40        50        60        70        80    
RNAi   ACATCATCGTCAGTAAAACGAAGTAGTCGACCGGAAAGTGCACGACAGGCACCAAGAGAT             
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 ACATCATCGTCAGTAAAACGAAGTAGTCGACCGGAAAGTGCACGACAGGCACCAAGAGAT 
     220       230       240       250       260       270          
 
             90       100       110       120       130       140    
RNAi   ACCACAGGATCCCTTTACTCAAATTTAACAGCTTCCTCATCAACAGTATCTGCGTGTTCG            
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 ACCACAGGATCCCTTTACTCAAATTTAACAGCTTCCTCATCAACAGTATCTGCGTGTTCG 
     280       290       300       310       320       330          
 
            150       160       170       180       190       200    
RNAi   GCGCCAGAAATTGTTGTGCTCAAAAAAGAGCAGGTGGTTTTGGCAGTAGATCATAAAGAT         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 GCGCCAGAAATTGTTGTGCTCAAAAAAGAGCAGGTGGTTTTGGCAGTAGATCATAAAGAT 
     340       350       360       370       380       390                        
 
            210       220       230       240       250       260    
RNAi   CAAGTGGACGAACAGAAAAAGAGGAATGAACAAGTGGTTAAGAAACCTGAGAAGTTAGAA         
       :::::::::::::::::::::: :::::::::::::::::::::::::::::::::::::  
unc-43 CAAGTGGACGAACAGAAAAAGAAGAATGAACAAGTGGTTAAGAAACCTGAGAAGTTAGAA 
     400       410       420       430       440       450                      
 
RNAi   GT         
       ::  
unc-43 GT       
     460  
 
unc-43-5’ RNAi vs. unc-43 spliced 
Comparison of: (A) ./wwwtmp/.30099.1.seq 5'RNAi unc-43-L 1094 bp                            
- 1094 nt (B) ./wwwtmp/.30099.2.seq unc-43e spliced 2505 bp                            
- 2505 nt  using matrix file: DNA (5/-4), gap-open/ext: -14/-4 E(limit)   0.05    
99.5% identity in 208 nt overlap (87-294:283-490); score: 1031 E(10000): 4.8e-77 
 
         90       100       110       120       130       140        
5'RNAi AGGGTGCCTTCTCAGTTGTTCGTCGTTGTGTTCATAAAACCACGGGCCTCGAGTTTGCTG         
       : ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 AAGGTGCCTTCTCAGTTGTTCGTCGTTGTGTTCATAAAACCACGGGCCTCGAGTTTGCTG              
            290       300       310       320       330       340   
 
 
           
 
        150       160       170       180       190       200        
5'RNAi CCAAAATCATCAACACAAAGAAGCTATCCGCTCGTGACTTTCAGAAACTTGAGAGGGAAG         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 CCAAAATCATCAACACAAAGAAGCTATCCGCTCGTGACTTTCAGAAACTTGAGAGGGAAG              
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            350       360       370       380       390       400             
 
 
        210       220       230       240       250       260        
5'RNAi CCAGAATTTGCAGAAAACTCCAGCATCCAAATATTGTTAGACTACACGACAGTATTCAAG         
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::  
unc-43 CCAGAATTTGCAGAAAACTCCAGCATCCAAATATTGTTAGACTACACGACAGTATTCAAG              
            410       420       430       440       450       460 
             
        270       280       290      
5'RNAi AGGAATCATTCCATTATCTGGTTTTTGA         
       ::::::::::::::::::::::::::::  
unc-43 AGGAATCATTCCATTATCTGGTTTTTGA              
            470       480       490 
 
120 
 
APPENDIX C 
SEQUENCE DATA FOR THE UNC-43 n498j037 ALLELE 
 
wt and UNC-43 n498j037 protein sequences 
 
unc-43 wt  
MMNASTKFSDNYDVKEELGKGAFSVVRRCVHKTTGLEFAAKIINTKKLSARDFQKLER
EARICRKLQHPNIVRLHDSIQEESFHYLVFDLVTGGELFEDIVAREFYSEADASHCIQQILE
SIAYCHSNGIVHRDLKPENLLLASKAKGAAVKLADFGLAIEVNDSEAWHGFAGTPGYLS
PEVLKKDPYSKPVDIWACGVILYILLVGYPPFWDEDQHRLYAQIKAGAYDYPSPEWDTV
TPEAKSLIDSMLTVNPKKRITADQALKVPWICNRERVASAIHRQDTVDCLKKFNARRKL
KVAICZ 
E108K = gf, D236 = catalytic domain residue conserved in 70% of all CaMKII 
orthologues/paralogues, T286 = autophosphorylation site, R283 = autoinhibitory domain residue 
that purportedly interacts with D236 
 
PJ1304 (D236N) 
MMNASTKFSDNYDVKEELGKGAFSVVRRCVHKTTGLEFAAKIINTKKLSARDFQKLER
EARICRKLQHPNIVRLHDSIQEESFHYLVFDLVTGGELFEDIVAREFYSEADASHCIQQILE
SIAYCHSNGIVHRDLKPENLLLASKAKGAAVKLADFGLAIEVNDSEAWHGFAGTPGYLS
PEVLKKDPYSKPVDIWACGVILYILLVGYPPFWDEDQHRLYAQIKAGAYDYPSPEWNTV
TPEAKSLIDSMLTVNPKKRITADQALKVPWICNRERVASAIHRQDTVDCLKKFNARRKL
KVAICZ 
D236N = CaMKII activity null substitution 
 
unc-43 n498j037 (PJ1304) vs. wt unc-43 
 
Comparison of:(A) ./wwwtmp/lalign/.12323.1.seq 1304mid                                            
- 771 nt(B) ./wwwtmp/lalign/.12323.2.seq wt                                              
- 2062 nt using matrix file: DNA, gap penalties: -14/-4 
 
  98.7% identity in 773 nt overlap; score: 3786 E(10,000): 5.3e-307 
 
 
 
               10          20        30        40        50         
1304mi TATTCTTTTNNNNNN--CTTTCNTAATTTTTTTTCGGTTTCAAAAGTTGTGATATATCTG 
       :::::::::        ::::: ::::::::::::::::::::::::::::::::::::: 
wt     TATTCTTTTGAAAACAACTTTCATAATTTTTTTTCGGTTTCAAAAGTTGTGATATATCTG 
      1270      1280      1290      1300      1310      1320        
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       60        70        80        90       100       110         
1304mi TGATTAATATCAGAAGAGATTTCTTTAAAAAAAATTACATTTTCAGCCAGAAAACTTGCT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
wt     TGATTAATATCAGAAGAGATTTCTTTAAAAAAAATTACATTTTCAGCCAGAAAACTTGCT 
      1330      1340      1350      1360      1370      1380        
 
      120       130       140       150       160       170         
1304mi TCTCGCATCTAAAGCGAAGGGAGCTGCTGTAAAGCTTGCCGATTTTGGTCTTGCAATCGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
wt     TCTCGCATCTAAAGCGAAGGGAGCTGCTGTAAAGCTTGCCGATTTTGGTCTTGCAATCGA 
      1390      1400      1410      1420      1430      1440        
 
      180       190       200       210       220       230         
1304mi AGTGAACGATAGTGAAGCATGGCACGGATTTGCTGGAACTCCAGGATACTTGTCGCCAGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
wt     AGTGAACGATAGTGAAGCATGGCACGGATTTGCTGGAACTCCAGGATACTTGTCGCCAGA 
      1450      1460      1470      1480      1490      1500        
 
      240       250       260       270       280       290         
1304mi AGTTCTCAAGAAGGATCCATACTCAAAGCCAGTTGATATCTGGGCTTGTGGTATGTATTT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
wt     AGTTCTCAAGAAGGATCCATACTCAAAGCCAGTTGATATCTGGGCTTGTGGTATGTATTT 
      1510      1520      1530      1540      1550      1560        
 
      300       310       320       330       340       350         
1304mi TAAAGTTTAATATTTCGAGTTAAGAATCTAATTTATAGGTGTCATTCTGTACATCCTTCT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
wt     TAAAGTTTAATATTTCGAGTTAAGAATCTAATTTATAGGTGTCATTCTGTACATCCTTCT 
      1570      1580      1590      1600      1610      1620        
 
      360       370       380       390       400       410         
1304mi TGTTGGATACCCACCATTCTGGGATGAGGACCAACACCGTTTATACGCACAAATCAAGGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
wt     TGTTGGATACCCACCATTCTGGGATGAGGACCAACACCGTTTATACGCACAAATCAAGGC 
      1630      1640      1650      1660      1670      1680    
     
      420       430       440       450       460       470         
1304mi TGGAGCCTATGATGTATGTTGAGCTTAAACTAGTTGAAACTATTTTAAAAATTCAAAATT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
wt     TGGAGCCTATGATGTATGTTGAGCTTAAACTAGTTGAAACTATTTTAAAAATTCAAAATT 
      1690      1700      1710      1720      1730      1740        
 
      480       490       500       510       520       530         
1304mi TCAGTACCCGAGCCCCGAATGGAATACGGTGACCCCGGAGGCAAAAAGCCTCATCGACAG 
       :::::::::::::::::::::: ::::::::::::::::::::::::::::::::::::: 
wt     TCAGTACCCGAGCCCCGAATGGGATACGGTGACCCCGGAGGCAAAAAGCCTCATCGACAG 
      1750      1760      1770      1780      1790      1800        
 
 
 
 
      540       550       560       570       580       590         
1304mi CATGCTGACGGTGAACCCAAAGAAGCGTATCACCGCTGATCAGGCCTTGAAAGTCCCATG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
wt     CATGCTGACGGTGAACCCAAAGAAGCGTATCACCGCTGATCAGGCCTTGAAAGTCCCATG 
      1810      1820      1830      1840      1850      1860       
122 
 
 
      600       610       620       630       640       650         
1304mi GATTTGCGTATGTTTTTTTTTGAATTATTTTTTGAATTCGAGAATTTATGATTTTCAAAT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
wt     GATTTGCGTATGTTTTTTTTTGAATTATTTTTTGAATTCGAGAATTTATGATTTTCAAAT 
      1870      1880      1890      1900      1910      1920        
 
      660       670       680       690       700       710         
1304mi TTTTCTATAAACATTTAAAGAATTTCAGAATCGCGAACGCGTTGCATCAGCTATCCACAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
wt     TTTTCTATAAACATTTAAAGAATTTCAGAATCGCGAACGCGTTGCATCAGCTATCCACAG 
      1930      1940      1950      1960      1970      1980        
 
      720       730       740       750       760       770  
1304mi ACAGGATACTGTTGACTGCTTGAAGAAATTCAATGCAAGGCGGAAGTTGAAGG 
       ::::::::::::::::::::::::::::::::::::::::::::::::::::: 
wt     ACAGGATACTGTTGACTGCTTGAAGAAATTCAATGCAAGGCGGAAGTTGAAGG 
      1990      2000      2010      2020      2030      2040 
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